An open clinical study to evaluate the clinical efficacy

of Siddha sasthric formulation “Pañcatīpākkiṉi cūraṇam”
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Dissertation submitted to 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
Chennai-32 
For the partial fulfilment in awarding the Degree of 
DOCTOR OF MEDICINE (SIDDHA) 
(Branch IV – Kuzhanthai Maruthuvam) 
 
DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
GOVERNMENT SIDDHA MEDICAL COLLEGE PALAYAMKOTTAI 
– 627 002 
OCTOBER-2019
` 
2 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE PALAYAMKOTTAI, 
TIRUNELVELI - 627002, TAMILNADU, INDIA 
Phone: 0462-2572736/2572737Fax: 0462-2582010 
Email:  gsmc.palayamkottai@gmail.com 
 
 
BONAFIDE CERTIFICATE 
This is to certify that the dissertation entitled “An open clinical study to evaluate 
the Clinical efficacy of Siddha sasthric formulation Pañcatīpākkiṉi cūraṇam for 
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Introduction: 
Present health care in India is a highly complex framework that is composed by 
different medical systems of varying provenance and vintage and is heavily 
influenced by the colonial history and politics. Multiple medical systems such as 
biomedicine, Siddha, Ayurveda, Unani, Homeopathy and Yoga contribute to the 
health sector in India [1]. Among this, Siddha and Ayurveda were indigenous medical 
systems practiced in southern and northern part of Indian subcontinent respectively 
and Yoga is a part of both the traditions. Though Unani came from West-Asia about 
eight hundred years ago and biomedicine, homeopathy and naturopathy entered from 
Europe before two hundred years ago, over a period of time, they contested with the 
indigenous systems and got acculturated in the Indian culture [2]. During the 
twentieth century, due to the colonial and post-colonial effects, biomedicine 
completely dominated the other medical systems and became the main stream of 
medicine in India. This critical change in health sector was cleverly implemented in 
the colonial India by introduction of various medical policies based on Macaulay’s 
minute on education. At present, medical systems other than biomedicine (including 
the indigenous medical systems that were the main stream of medicine for centuries) 
were considered as complementary /alternative medical systems and is grouped under 
AYUSH (Ayurveda, Yoga, Unani, Siddha and Homeopathy) [3]. Moreover, they have 
undergone a drastic change in many aspects. Though the indigenous medical systems 
were previously taught only on kuru-cīṭaṉ basis, during twentieth century, they were 
institutionalized similar to the western biomedicine in-order to be in compliance with 
the government policies [4]. This forceful adaptation of the policies of western 
biomedicine created a negative effect on the survival and growth of traditional Indian 
medicines. 
Traditional Indian systems in general and Siddha in particular did not view the 
body as replaceable compared to enduring soul inside, rather it sort to preserve the 
material body which is the substratum for the soul. In the Siddha view, the body is 
Introduction 1 
 2 
 
 
2 Introduction 
more than an organ system and disease cannot be accounted for organs alone[5]. It 
believes that the body is divided into different substrata and the healthiness of the 
substrata depends on the factors that nourish them. Gross body (stūla uṭal) is 
nourished by gross substances like food and water whereas subtle body (cūkkuma 
uṭal) is nourished by subtle substances like pirāṉaṉ thoughts and intellect [6]. These 
concepts are completely contrary to the biomedicine, which is laboratory centric and 
the diseases are gauged in terms of parameters that are measurable and can be 
demonstrated experimentally. The anatomical classification of body by western 
system does not go beyond the facts that can be observed in a cadaver. But the Indian 
traditional medicine system deals only with a living body because one can never study 
the flow of pirāṉaṉ or the thoughts in a dead body. Such a detailed knowledge can be 
obtained only after million years of usage and experience. The above discussions 
clearly highlight the epistemological and pedagogical difference between the 
contemporary biomedicine and Indian traditional medicine which contributes to the 
major challenge in the growth of Siddha.  
Practically, it will be very difficult task for a Siddha physician to convince a patient 
by using a Siddha disease terminology, as most of the present Indian population is 
only aware of the disease terminologies of biomedicine and expect a Siddha physician 
to address the disease with the same. As Siddha classification of diseases are 
completely different from those of the biomedical classification, it is almost 
impossible to make one to one correlations or pick up equivalent terms. However, 
these intuitivemind-sets of the population have grown due to the inherent belief in the 
“superiority” of biomedicine and this has forced the Siddha practitioners to adopt both 
biomedical and Siddha disease terminologies in daily practice. Though this is not a 
healthy sign, Siddha practitioners have to accept and adopt few of the concepts 
followed by western biomedicine without losing the real essence of Siddha system in 
order to address the apprehensions among the public in consuming a Siddha drug. 
Hence in this work, an attempt was made to understand the effect of a traditional 
Siddha drug Pañcatīpākkiṉi cūraṇam (PDC), in treating the disease Āma kaḻiccal 
  
(AK) based on Siddha system of disease classification by employing various voguish 
techniques of western biomedicine 
` 
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Aim: 
 This study aims to clinically evaluate the effect of Pañcatīpākkiṉi cūraṇam (PDC) in 
children affected by Āma kaḻiccal (AK). In order to attain these following primary 
objectives were framed 
Primary objectives: 
 Preparation and characterization of PDC 
 Establish the safety and efficacy of PDC in animal models. 
 Understand the effect of PDC in management of AK in young children 
In order to achieve these primary objectives, following secondary objectives were 
framed. 
Secondary objectives: 
 Identification, collection and authentication of raw materials of PDC 
 Purification of raw materials and preparation of PDC 
 Characterisation of PDC as per PLIM guidelines 
 To evaluate the acute oral toxic effect of PDC in rat models as per OECD 
guidelines. 
 To evaluate the 28-days repeated oral toxic effect of PDC in rat models as per 
OECD guidelines. 
 To evaluate the effect of PDC in modifying the intestinal transit time in rat 
models. 
 To evaluate the anti-diarrhoeal effect of PDC in rat models. 
 Clinical evaluation of characters of AK through Siddha and biomedical 
parameters. 
 Clinical evaluation of effect of PDC in management of AK through Siddha 
and biomedical parameters. 
Aims and Objectives 1-A 
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eview of literature: 
 
 
 
Review of Siddha literature: 
‘Kaḻiccal’ refers to any undue looseness of the bowls, commonly caused due to eating 
of unsuitable food, vapid or tasteless cold rice, sudden changes in weather, chillness 
or from sudden fear, excitement etc[7]. Whereas ‘athisaaram’ and ‘Kirāṇi’ refers to 
chronic (caused by aggravation of wind or all toads) and acute diarrhoea (marked by 
serous stools) respectively. Different types of classification of kaḻiccal are given in 
table. 2.1. Siddha maruthuvam, a siddha text followed by institution based Siddha 
scholars classifies kaḻiccal into 3 types: PeruṅkaḻIccal, NiṇakkaḻIccal, Kaṭuppuk 
kaḻiccal. Peruṅ kaḻiccal and Niṇak kaḻiccal. In turn are further subclassified based on 
mukkuṟṟam into four and twelve types respectively.  
General classification of ‘Kaḻiccal’in Siddha: 
Siddha texts describe diarrhoea by different terms such as ‘kaḻiccal’, ‘athisaaram’ 
and ‘Kirāṇi’.  
Table 2.1: Classification of Kaḻiccal documented in various in Siddha texts 
Potu 
Maruttuvam 
1.Peruṅkaḻiccal 
1. Vaḷi Peruṅkaḻiccal 
2. Aḻal Peruṅkaḻiccal 
3. Aiyam Peruṅkaḻiccal 
4. Mukkuṟṟam Peruṅkaḻiccal 
5. Cūrap Peruṅkaḻiccal 
6. Tōṭap Peruṅkaḻiccal 
7. Payam Peruṅkaḻiccal 
8. Tukkam Peruṅkaḻiccal 
9. Kurutik Peruṅkaḻiccal 
2.Niṇakkaḻiccal 
1. Vaḷi Niṇakkaḻiccal 
2. Aḻal Niṇakkaḻiccal 
3. Aiyam Niṇakkaḻiccal 
4. Mukkuṟṟam Niṇakkaḻiccal 
5. Aḻaṟkāl Niṇakkaḻiccal  
6. Kuṭaṟkāl Niṇakkaḻiccal  
7. Kīḻ Vāyuk Niṇakkaḻiccal 
8. Kuṉmak Niṇakkaḻiccal  
9. Cūl Niṇakkaḻiccal  
10. Oṭṭu Niṇakkaḻiccal 
11. Ericcal Niṇakkaḻiccal 
3.Kaṭuppuk 
Kaḻiccal 
 
4.Ūḻi 
1. Vaḷi Ūḻi 
2. Aḻal Ūḻi 
3. Aiyam 
Ūḻi 
 
T.V. 
Sambasivam 
Pillai 
Medical 
Dictionary  
1. Cītak Kaḻiccal 
2. Rattak Kaḻiccal 
3. Calak Kaḻiccal 
4. Caṅkarak Kaḻiccal 
5. Cōpak Kaḻiccal 
6. Veḷḷuṭaik Kaḻiccal 
7. Vayiṟṟuk Kaḻiccal 
Review of literature 2 
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Table 2.2:General classification of Kirāṇi  documented in various Siddha texts (ref) 
Yūkimuṉi Vaittiya 
Cintāmaṇi 
Aṉupava Vaittiya Tēva 
Rakaciyam 
Yūkimuṉi Vaittiya 
Kāviyam 
Carapēntirar Vaittiya 
Muṟaikaḷ 
1. Vātak Kirāṇi 
2. Pitta Kirāṇi 
3. Cilēttuma Kirāṇi   
4. Tonta Kirāṇi  
5. Uṣṇavāyu Kirāṇi  
6. Arttarā Kirāṇi  
7. Mūlavāyu Kirāṇi  
8. Kuṉma Kirāṇi  
9. Karppa Kirāṇi 
10. Oṭṭu Kirāṇi  
11. Caṅkirakak 
Kirāṇi 
1. Uṣṇavāu Kirāṇi   
2. Antaravāyu Kirāṇi   
3. Mūlavāyu Kirāṇi   
4. Kuṉma Kirāṇi   
5. Karppa Kirāṇi   
6. Oṭṭu Kirāṇi   
7. Caṅkira Kirāṇi 
1. Vātam  
2. Pittam  
3. Kapam  
4. Pittakapam 
5. Irattam  
6. Vāyuviṉāl 
Uṇṭākum Kirāṇi 
1. Vātak Kirāṇi 
2. Pitta Kirāṇi  
3. Cilēttuma Kirāṇi  
4. Tiritōca Kirāṇi 
 
Different types of classification of Kirāṇiis given in table. 1.3. Though Yūkimuṉi 
Vaittiya Cintāmaṇi, Yūkimuṉi Vaittiya Kāviyam and Carapēntirar Vaittiya 
MuṟaikaḷclassifiesKirāṇiprimarily based on themukkuṟṟam, Sub-classification of 
Kirāṇiin Aṉupava Vaittiya Tēva Rakaciyam is completely based on cause and 
symptoms. Altogether a significant variation could be noted among all the four texts 
analysed 
Table 2.3: General classification of Aticāram documented in various Siddha texts (ref) 
Yūkimuṉi Vaittiya 
Cintāmaṇi 
Aṉupava Vaittiya Tēva 
Rakaciyam 
Ātmaraṭcāmirtam 
Eṉum Vaittiya 
Cāracaṅkirakam 
Carapēntirar Vaittiya 
Muṟaikaḷ 
1. Vāta Aticāram  
2. Pitta Aticāram  
3. Cilēttuma 
Aticāram  
4. Tiritōca Aticāram  
5. Cura Aticāram 
6. Caṉṉipāta 
Aticāram  
7. Tōṣā Aticāram 
1. Vāta Aticāram  
2. Pitta Aticāram  
3. Cilēttuma 
Aticāram  
4. Tiritōca Aticāram 
5. Payam Aticāram  
6. Tukka Aticāram 
7. Manta Aticāram  
8. Ratta Aticāram 
1. Vāta Aticāram  
2. Pitta Aticāram  
3. Cilēttuma 
Aticāram 
4. Aticāra Tōṭam 
5. Cura Aticāram 
1. Vāta Aticāram 
2. Pitta Aticāram  
3. Cilēttuma 
Aticāram  
4. Tiritōca Aticāram  
5. Payam Aticāram  
6. Tukkam Aticāram  
7. Rattam Aticāram 
 
All the four known siddha texts that describe about Aticāram (Yūkimuṉi Vaittiya 
Cintāmaṇi, Aṉupava Vaittiya Tēva Rakaciyam, Ātmaraṭcāmirtam Eṉum Vaittiya 
Cāracaṅkirakam and Carapēntirar Vaittiya Muṟaikaḷ) are fundamentally based on the 
  7 
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difference inmukkuṟṟam. However, Yūkimuṉi Vaittiya Cintāmaṇi, Aṉupava Vaittiya 
Tēva Rakaciyam, and Carapēntirar Vaittiya Muṟaikaḷ also give importance to signs 
and symptoms to few extents. 
Classification of Paediatric diarrhoea in Siddha: 
Different school of thoughts espoused in various paediatric Siddha texts with respect 
to classification of diarrhoea in children is tabulated in table. 1.5.  
Table 2.4: Classification of Kaḻiccal (diarrhoea) found in various paediatric siddha texts 
Kuḻantai 
Maruttuvam 
& 
Pararācacēkara 
Vaittiya Kaiyēṭu 
Matalai Noy 2 
Kōpāla 
Paṉikkar 
Ācāṉ Pāla 
Vākaṭam 
Kumpa 
Muṉi Pāla 
Vākaṭam 
Piḷḷai Piṇi 
Maruttuvam 
 
1. Nīrppāṭu  
2. Nīrpaṭuvaṉ  
3. Ceriyāppaṭuvaṉ  
4. Īraṟpaṭuvaṉ  
5. Rattapaṭuvaṉ  
6. Toṅkal Kaḻiccal  
7. Vayiṟṟukkaṭuppu  
8. Vayiṟṟuḷaivu 
9. Vayiṟṟukkotippu  
10. Mūlakkotippu   
 
and 
 
1. Āma  
2. Kaṇa  
3. Manta 
1. Pāl  
2. Varaḷ  
3. Vānti  
4. Irai  
5. Kaṇai  
6. Mānta  
7. Veppu   
8. Porumal   
9. Aticāra   
10. Cuḻimāntam   
11. Āma   
12. Viṭā   
13. Paccilai   
14. Iraimāntam   
15. Tōṭa   
16. Kaṭuppu   
17. Ratta   
18. Cala 
1. Aticāra  
2. Āma  
3. Ratta  
4. Kaṇai  
5. Cala  
6. Cura  
7. Tōṭa  
8. Paccilai  
9. Pal 
Muḷaikku
m Pōtu 
Kaḻiccal   
10. Pāl 
1. Pāl  
2. Piraḷi  
3. Mānta  
4. Retta  
5. Kaṇai  
6. Āmai 
1. Aticāra  
2. Āma  
3. Niṇa 
T.V. 
Sambasivam 
Pillai Tamil 
dictionary 
Pāla Vākaṭam 
1. Cītak  
2. Rattak  
3. Calak 
4. Caṅkarak  
5. Cōpak 
6. Veḷḷuṭaik 
7. Vayiṟṟuk 
1. Āma  
2. Kaṇa  
3. Manta 
 
Contrary to the general Siddha literatures, which describe diarrhoea based on three 
terms: kaḻiccal, Kirāṇi and athisaaram, pediatric Siddha literatures use only kaḻiccal 
to address diarrhoea.However, Kōpāla Paṉikkar Ācāṉ Pāla Vākaṭam and Piḷḷai Piṇi 
Maruttuvam hasAticāram kaḻiccal as sub-classification of kaḻiccal. Though matalai 
noy, name eighteen types of kaḻiccal, detail descriptions werefound only for thirteen 
among them. Pāl kaḻiccal, Ratta kaḻiccal andAticāra kaḻiccal weredescribed only in 
Matalai Noy, Kumpamuṉi Pāla Vākaṭam and Kōpāla Paṉikkar Ācāṉ Pāla Vākaṭam. 
One possible reason for this could be the influence of geographical location.As all 
these three books belongs to ancient thiruvithangoor samasthaanam(southernmost 
part of present day Tamil Nadu and Kerala), it can be plausibly concluded that these 
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three forms of kaḻiccal were predominant only in thrivithangoor region. Another 
reason could be the difference in linguistic nature of these texts (mixed use of both 
Malayalam and Tamil words) from rest of the availableSiddha texts. As all the 
classifications were not described in detail, the chances of same disease being referred 
by different names due to linguistic variations could not be completely ruled out. Pāl 
kaḻiccal has been described as milky flour like diarrhoeain kōpāla paṉikkar ācāṉ pāla 
vākaṭam and as a diarrhoeal disease characterised by abdominal bloating, green 
coloured and curdy stools, fatigue, excessive sleep, vomiting, giddiness, fever, 
drooping of eyelids, pale and cool limbs in kumpamuṉi pāla vākaṭam. No descriptions 
of Pāl kaḻiccal could be noted in Matalai Noy. Kumpamuṉi pāla vākaṭam describes 
ratta kaḻiccal as uncontrolled vomiting following breastfeeding, fatigue, abdominal 
pain, diarrhoea with mucus, pus or blood, aphthous ulcer, head ache, fever, excessive 
`thirst, dryness of tongue, tremor, joint pain, anal pain followed by rectal prolapse, 
loss of weight and cyanosis. Whereas, matalai noy and kōpāla paṉikkar ācāṉ pāla 
vākaṭam characterize ratta and kaḻiccalas bloody diarrhoea, abdominal pain, coated 
tongue, anal pain and bloating as major symptoms. Kuḻantai Maruttuvam and 
Pararācacēkara Vaittiya Kaiyēṭu describe paduvan and kothippu as a sub-
classification of kaḻiccal which represents cholera (Ūḻi) and thodam respectively. 
Apart from this,toṅkal kaḻiccalis described only in Kuḻantai Maruttuvam and 
Pararācacēkara Vaittiya Kaiyēṭu as a pediatric disease characterised by greeny 
diarrhoea due to ingestion of hair or foreign particles. Diarrhoea during teething is 
described as a separate classification only in Kōpāla Paṉikkar Ācāṉ Pāla 
Vākaṭam.Among the various diarrhoeal classifications mentioned above, āma 
kaḻiccal, kaṇakaḻiccal, manta kaḻiccal were common amongmost of the authors. This 
indicates that three these types are more prevalent in majority of population during 
different seasons and geographical location.  
Āma kaḻiccal- Overview: 
The term āma kaḻiccal (AK) literally means diarrhoea with mucus. Though many 
Siddha texts consider this as a disease of all age groups, most of the paediatric Siddha 
texts consider this as a paediatric disease that requires immediate medical attention. 
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Description about AK has been documented in various Siddha classics (shown in table 
4.1). Pararācacēkaram, a paediatric Siddha classic of Sri Lankan origin statesAK as a 
diarrhoeaaccompanied by mucus or blood or both with abdominal pain. These were 
similar to the 
descriptions in 
Kōpāla paṉikkar 
ācāṉpālavākaṭam, 
which dictates AKin 
children as a disease characterised by fever with chilled limbs, bloating and diarrhoea 
with blood stained stool and vomiting. Analogously, Piḷḷaippiṇi maruttuvam, 
ascertainAKas a paediatric disease 
associated with headache, nausea, 
vomiting, abdominal pain, sore 
anus, abdominal flare (vayiṟu puraṭṭal) in initial stages followed by diarrhoea and 
mucoid stools in later stages. It further states that after 2 to 3 times of diarrhoea, 
abdominal pain and sore anus gets aggravated, resulting in stools with fresh blood and 
mucus and defecation will be highly painful with 50-60 times per day. Quite contrary 
to this, Pālavākaṭam[8], the textbook followed by institutional based Siddha scholars, 
does not include diarrhoea as major symptom and says that AK in infants is 
characterised by regurgitation of breast milk, fatigue, anaemia (irattam cuṇṭum), 
pyrexia, low pitched voice and tirednessin both limbs. Kōṣāyi aṉupōka vaittiya 
piramma irakaciyamand Matalai nōy[9] vouches this as both the texts describe AK as 
a disease in infants characterised by regurgitation of breast milk, flatulence, blood 
discharge, fever, low pitched voice and chillness of both limbs.Gripping pain below 
umbilicus, respiratory distress, mucoid stools and loss of appetite were the characters 
of AK described in Taṉvantiri vaittiyam.  Rivetingly, Tamil medical dictionary by T. 
V. Sambasivampillai, cite AKas Tamil description of catarrhal enteritis and is 
characterised by loss of appetite, fever, painful urination, nausea, vomiting, pain in 
the rectum and abdomen, stools mingled with mucus or blood or blood or both, dry 
tongue, pale and anxious face straining during defecation and scanty and high 
coloured urine. This also states that this is caused due to specific inflammation and 
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ulceration of the mucus living of the large intestine resulting in phlegmatic 
evacuations in which the stool is mixed with mucus. 
Table 2.5: Descriptions about documented in different Siddha classics 
Siddha text Description about āma kaḻiccal 
Pararācacēkaram  Diarrhoea with either mucus or blood or both with abdominal pain 
Kumpamuṉi pālavākaṭam Loss of weight, respiratory distress with flatulence, vomiting and diarrhoea, dry tongue, 
sunken and pale eyes, green coloured stools, blood and mucus stained stools, nasal 
dripping, chillness of both limbs, fatigue and tremors 
Taṉvantiri vaittiyam Gripping pain below umbilicus, respiratory distress, mucoid stools  and loss of appetite 
Kōpāla paṉikkar ācāṉ 
pālavākaṭam 
Bloating and diarrhoea, blood stained stool with vomiting and fever with chilled limbs 
Matalai nōy Regurgitation of breast milk, flatulence, blood discharge, fever and chillness of both limbs 
Kōṣāyi aṉupōka vaittiya 
piramma irakaciyam 
Regurgitation of breast milk, flatulence, blood discharge, fever, chillness of both limbs 
and low pitched voice 
Pālavākaṭam Regurgitation of breast milk, fatigue, fever, tiredness in both limbs, low pitched voice and 
anaemia 
Piḷḷaippiṇi maruttuvam Headache, nausea, vomiting, abdominal pain, sore anus, abdominal flare (vayiṟu puraṭṭal) 
in initial stages followed by diarrhoea and mucoid stools with fresh blood in later stages. 
T. V. Sampasivampillai 
Medical dictionary 
Loss of appetite, fever, painful urination, nausea and vomiting, pain in the rectum and 
abdomen, stools mingled with mucus or blood or both, dry tongue, pale and anxious face, 
straining during defecation, scanty and high coloured urine. 
It is said to be indirectly due to chill weather and moist air residence in damp places, 
drinking impure water, heavy food, which excites wind etc. This is corroborated by 
Kōpāla paṉikkar ācāṉ pālavākaṭam which states that AK is primarily due to 
inflammation of digestive organs, large intestine and small intestine. When analysing 
all these literatures, it could be easily noted that diarrhoea with blood or mucus or 
both was the most common symptom mentioned in the five out of the eight siddha 
texts that describe about AK. Regurgitation of milk, flatulence and fever with 
chillness in both the limbs was also mentioned as major symptom of AK in significant 
number of Siddha texts. Other symptoms include fatigue, anaemia, low pitched voice, 
dry tongue, sunken and pale eyes, nausea and vomiting, scanty and high coloured 
urine, gripping pain below umbilicus, loss of appetite, nasal dripping and respiratory 
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distress. However, Taṉvantiri vaittiyam, kōṣāyi aṉupōka vaittiya piramma irakaciyam 
and Pālavākaṭam did not include diarrhoea with blood and mucus as characteristic 
symptom of AK. This can be due to the fact that sometimes, probably depending on 
age, sex, geographical location, seasonal variation and individual genotype the 
symptomatic manifestation of disease may vary. Moreover, it is also understandable 
that AKmay show loss of appetite, flatulence, nasal dripping, respiratory distress, 
fever, nausea and vomiting in initial stages followed by diarrhoea, mucoid stools, and 
blood containing stools in later stages. Dry tongue, sunken eyes, fatigue, low voice, 
and chillness of legs 
could possibly be due 
to the dehydration 
caused by diarrhoea. 
As bloody 
mucopurulent diarrhoea accompanied by dehydration is common among various types 
of enteritis in children. Various factors such as infection, drugs, psychological, 
environmental, autoimmune disorders etc were considered to be the major culprits in 
most of the enteritis in children. Hence in the present study, all these criteria were 
taken in to consideration while recruiting the subjects. 
Review of modern literature: 
Diarrhoea – Overview: 
Despite the rapid advancement of various therapeutic techniques in the past three 
decades, diarrhoea remains as the second leading cause of death among children 
under five years of age worldwide[10]. It is estimated that diarrhoea accounted for 
9.9% of the 6.9 million deaths among children under 5 in 2011[10]. India recorded the 
largest number of under-5 deaths in 2015, at 1·3 million, followed by Nigeria and 
Pakistan [10].  Though most of the diarrhoea in children is associated with infections, 
other causes such as malnutrition, indigestion, drugs, psychological disturbances and 
few physiological processes such as teething also contributes to diarrhoea.  
Normal fluid and electrolyte movement are inextricably linked to diarrhoea. 
Approximately 6 to 8 litres of fluid enter the small intestine per day. Among this, only 
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1.5 litres are contributed from the diet; the remainder of the overall fluid load is made 
up of gastric, salivary, pancreatic, and biliary secretions. Approximately 5.5 to 6 litres 
of fluid are absorbed in small intestine and only 1.5 to 2 litres of fluid enters large 
intestine. But colon has the capacity to absorb 4.5 to 5 litres per day. So, almost all the 
fluid (1.5 to 2 litres) entering colon will be reabsorbed and less than 100 to 200 ml of 
fluid is excreted via stools per day. This clearly shows that the colon is a more 
efficient absorptive organ than the small intestine. If there is a decrease in small 
intestinal fluid absorption, regardless of cause, diarrhoea will not develop until the 
absorptive capacity of the colon is exceeded. On the other hand, relatively small 
decreases in colonic absorption can lead to substantial increases in stool water 
excretion, and diarrhoea will result. Although most discussions of diarrhoea are 
concerned with water excretion, it is important to bear in mind that all gastrointestinal 
water flow is a result of solute movement. Water absorption is secondary to solute 
absorption, and water secretion follows solute secretion. Therefore, information on 
the body’s ability to absorb and secrete sodium and chloride is crucial to the 
understanding of cellular events in acute diarrhoea.  
General mechanism of Diarrhoea: 
Several mechanisms may account for these alterations in fluid movement; these 
include  
1. Increased luminal osmolality  
2. Decreased fluid absorption 
3. Increased intestinal secretion 
4. Altered intestinal motility 
Primary lactase deficiency will always resultin increased luminal osmolality. 
Decrease or absence of lactase, a brush-border enzyme of the small intestine, results 
in indigestion of dietary lactose, leading to the formation of a variety of short-chain 
fatty acids, carbon dioxide, and hydrogen. The resulting increase in luminal 
osmolality causes altered fluid movement and diarrhoea.  
Diminished absorption of fluid and electrolytes is often secondary to mucosal damage 
in either the small or the large intestine. Any damage to jejunal villi resulting in 
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histologic abnormalities and mucosal inflammation of jejunumsubstantially decrease 
the mucosal absorptive function leading to diarrhoea.  
Active electrolyte secretion is the third mechanism causing alterations in fluid and 
electrolyte movement. Agents that stimulate secretion, known as secretagogues, may 
be present in the small and large intestine. They are heterogeneous and frequently 
responsible for several diarrhea1 disorders. Intestinal secretagogues can be classified 
into three groups:  
1. Bacterial enterotoxins 
2. Hormones (either circulating or present as paracrine mediators) 
3. Detergents (including bile acids, fatty acids, and commercial laxatives)  
All of the secretagogues stimulate active chloride secretion, thus affecting sodium and 
chloride movement. For example, in toxigenic diarrhoea caused by in Escherichia 
coli, heat labile (or LT) enterotoxin stimulates active chloride secretion resulting in 
excess fluid secretion. The enterotoxins, however, do not usually cause structural 
damage to the small intestine nor alter absorptive function.  
Hormones that increase intestinal secretion include vasoactive intestinal peptide, 
serotonin, and calcitonin. Prostaglandin El, which stimulates adenylate cyclase and 
increases mucosal cyclic adenosine monophosphate levels, has also been implicated 
as the mediator of diarrhoea in psychological disorders. Diarrhoea also has been noted 
as an adverse effect of prostaglandin administration. Although vasoactive intestinal 
peptide affects ion transport by increasing intracellular cyclic adenosine 
monophosphate levels, other secretagogues (e.g., serotonin) alter ion transport by 
acting as a calcium ionophore.  
The mechanism by which fluid and electrolyte movement is affected by alterations in 
intestinal motility is not clearly understood. The precise relations between changes in 
motor function, changes in intraluminal pressure, changes between intraluminal 
pressure, and intestinal transit time need to be clarified.  
Infection and diarrhoea: 
Diarrhoea due to infection accounts for more than 90% of paediatric diarrhoea and is 
caused by various Enteropathogens such as bacteria, virus, protozoan and other 
pathogens[11]. Among the various viruses associated with diarrheal disorders, 
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rotavirus is the leading cause of death with 38.3% of the total deaths due to infection, 
followed by Calcivirus (13.8%), Adenovirus (4.3%) and Astrovirus (3%). Among the 
bacteria, enteropathogenic Escherichia coli top the list with 15.3%, followed by 
enterotoxigenic Escherichia coli (6.9), Shigella spp (4.7), Campylobacter spp (4.3%), 
Salmonella spp (3.5), and Vibrio cholerae (1.8%). Other species such are Giardia 
lamblia (3.1%), Cryptosporidium spp (2.7) and Entamoeba hystolitica (0.3) also 
contributes to the paediatric diarrhoea. [11] various factors such as seasonal change, 
poor nutrition, low economic status, improper hygiene, inadequate breast feeding 
enhance the chances of infection. Studies have shown that as many as one-half to two-
thirds of children with severe acute malnutrition present with diarrhoea. Under 
nutrition precipitates deaths due to diarrhoea, and similarly, diarrhoea often leads to 
severe acute malnutrition in young children [12]. Enteropathogens that cause 
diarrhoeas affect the physiology of the gut in different ways. By modifying the 
equilibrium of water and electrolytes, they induce different types of diarrhoea. Thus, 
osmotic diarrhoeas result from an excess of non-absorbable and osmotically active 
solutes in the lumen and secretory diarrhoea results when the secretory activity of the 
mucosa exceeds its absorption capacity [13]. 
Diarrhoea and indigestion: 
Indigestion could be directly related with the daily food habits and indirectly related 
with nature, type and quantity of food consumed. As early as 10th century, Avicenna 
stated cow’s milk as cause of diarrhoea in infants and advised milk free diets [14]. 
High dietary fat was considered to be the major culprit in paediatric diarrhoea due to 
indigestion and the chances of diarrhoea are more in subjects with defective bile 
production. Children known to have gall stones or undergone cholecystectomy will 
have frequent diarrhoea due to defective bile secretion. Even in normal subjects 
repeated consumption of high fat diet will lead to diarrhoea after certain period of 
time [15] 
Diarrhoea and drugs: 
As intestinal mucosa is the first absorption site of orally administered drugs, incidence 
of drug-induced diarrhoea is relatively high. Diarrhoea contributes for about 7 per 
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cent of all drug adverse effects[13] and up to 4 per cent of people suffering from 
diarrhoea are induced as a side effects of prescribedmedications [16]. Antibiotic-
associated diarrhoea are responsible for 25 per cent of drug-induced diarrhoea[17]. 
The mechanism of drug-induced diarrhoea is often multifactorial and sometimes 
remains unclear. More than 700 drugs have been implicated in causing diarrhoea; 
those most frequently involved are antimicrobials, laxatives, magnesium- containing 
antacids, lactose- or sorbitol-containing products, nonsteroidal anti- inflammatory 
drugs, prostaglandins, colchicine, antineoplastics, antiarrhythmic drugs and 
cholinergic agents[13]. New drugs are likely to induce diarrhoea because of their 
pharmacodynamics properties, for example, lipase inhibitors and cholinesterase 
inhibitors. Several pathophysiological mechanisms[16, 17]are involved in drug-
induced diarrhoea: osmotic diarrhoea, secretory diarrhoea, shortened transit time, 
exudative diarrhoea and protein-losing enteropathy, and malabsorption or 
maldigestion of fat and carbohydrates. Often 2 or more mechanisms are present 
simultaneously. Major pathological mechanisms of drug induced diarrhoea are 
described in figure. 2.1. 
The disease spectrum of antibiotic-associated diarrhoea ranges from benign diarrhoea 
to potentially life-threatening pseudo-membranous colitis (reported in 10% of patients 
receiving clindamycin). Most frequently, however, diarrhoea is benign, appearing 
during the first days of treatment, whatever the class of antibacterial, and resolving 
spontaneously after discontinuation of treatment[18].Paediatric data regarding the 
prevalence of drug induced diarrhoea is scarce with very few studies all over the 
world and no Indian studies[19].However, globally, the rate of antibiotic-associated 
diarrhoea in children seems to be  around 11% in the youngest children[20]. 
Antibiotics cause diarrhoea by several mechanisms. First, suppression of anaerobic 
bacteria by drugs such as aminopenicillins, cephalosporins, and clindamycin results in 
reduced metabolism of carbohydrates leading to osmotic diarrhoea [17]. 
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Figure 2 1:Major pathophysiological mechanisms of drug-induced diarrhoea [16] 
Second, antibiotics may change the gut flora resulting in overgrowth of potentially 
pathogenic organisms such as Clostridium difficile, Salmonella, Clostridium 
perfringens type A, Staphylococcus aureus, and Candida albicans. Finally, antibiotics 
with prokinetic activity, such as erythromycin and clavulanate, promote 
diarrhoea[21]. Antibiotic-associated diarrhoea has a spectrum of severity including 
uncomplicated diarrhoea, colitis and pseudo- membranous colitis. Epidemiologic 
studies are limited to the clinical description of non-C. Difficile-associated cases, but 
C. difficile AAD has also been well described. In the general healthcare-associated 
population, most of the cases of C.difficile AAD are uncomplicated diarrhoea (10–30 
out of 100 patients), while colitis is less frequent (5–10 out of 100 patients) and 
pseudo- membranous colitis is infrequent (0.1–1 out of 100 patients)[18].  
  17 
17 Literature review 
Dentition and diarrhoea: 
Despite being a natural process of child development, the impacts of primary tooth 
eruption in diarrhoea of children has been debated for many centuries, and traditional 
beliefs on the issue have still not been entirely supplanted by scientific findings[22]. 
Hippocrates mentions that if dentition is associated with diarrhoea, the chances of the 
child getting convulsions are very limited, whereas if the child gets constipation 
during teething, the chance of getting convulsions is more. Work by few well know 
ancient physicians such a Aristotle, Homer, Celsus, and others vouch the association 
between diarrhoea and tooth eruption. 
Table 2.6: Drugs used in management of 
diarrhoea during dentition in Siddha 
Avicenna recommends a milk free diet 
consisting of goat’s cheese in cold water, egg 
yolk, and bread or wheat flour boiled in water 
in infants with intractable diarrhoea during 
teething [14]  Atharva-veda recommends a 
prayer and special diet for prevention of complications of teething in children. Few 
Siddha literatures also recommend specific medications for management of diarrhoea 
during teething in children (shown in table 2.6).  Though it’s been believed that 
teething is associated with diarrhoea in earlier stages, it’s been strongly criticised by 
many physicians as early as 17th century. However, in 1839, 5016 deaths in England 
and Wales were attributed to teething [23]. Most medical professionals now agree that 
teething does not cause life-threatening illness, but they disagree about which 
symptoms may be associated with tooth eruption.  
Anxiety, fear and diarrhoea: 
Anxiety and fear may cause diarrhoea, while depressed patients are four to five times 
more likely to report constipation [13].Diarrhoea predominant irritable bowel 
syndrome is a diarrhoeal disease precipitated by anxiety, fear, depression or anger and 
is viewed as resulting from the interactions of a number of factors, such as abnormal 
gastrointestinal motility, visceral hypersensitivity, and psychosocial factors [24]. A 
growing attention on the interaction between the central and enteric nervous systems 
has led to the suggestion that the disease could be related to a hyper reactivity of the 
1. Iraṭṭai Pēymiraṭṭi (Leaf Juice) 
2. Thiratchai ( Fruit Juice) 
3. Tāḷicapattiri (Leaf Juice- 5-10 Drops) 
4. Juice of vāḻaippū, puḷiyārai and tuḷaci 
extracted by steam cooking 
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brain-gut axis, which is a model describing bidirectional pathways linking emotional 
and cognitive areas in the central nervous system with visceral afferent sensation and 
intestinal function.Diarrhoea predominant irritable bowel syndrome subjects showed 
increased number of enter endocrine cells and postprandial plasmatic serotonin levels 
and were always associated with high rates of psychiatric comorbidity and history of 
sexual abuse [25]. Serotonin is widely distributed throughout the gut within both the 
enteric nerves and enterochromaffin (EC) cells. EC cells are located in the gut mucosa 
with maximal numbers in the duodenum and rectum where they act as signal 
transducers, responding to pressure and luminal substances both bacterial and dietary. 
Activation leads to serotonin release which acts on a range of receptors on mucosal 
afferent and myenteric interneurons to initiate secretomotor reflexes. These cause 
nausea and vomiting as well as intestinal secretion, propulsion and if pronounced, 
diarrhoea [26]. 
Conventional Management of diarrhoea: 
Therapeutic feeding strategies 
 Management of Diarrhoea in children primarily include diet restrictions followed by 
symptomatic management. Current WHO guidelines on the management and 
treatment of diarrhoea in children strongly recommend continued feeding alongside 
administration of oral rehydration solutions, plus zinc therapy [27]. Continued feeding 
is now widely accepted as a key component of appropriate treatment for childhood 
diarrhoea, but with the exception of consensus on continued breastfeeding, there 
remains some debate regarding the optimal diet or dietary ingredients for hastening 
recovery and maintaining nutritional status in children with diarrhoea. Lactose 
malabsorption is a common complication of diarrhoea, especially among 
malnourished children.So, limiting milk intake among young children can promote 
further nutritional deficiency if substitute sources of protein and energy are not 
consumed sufficiently. Hence, any commercial lactose-free formulations or soy-based 
preparations may be effective alternative to milk. 
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For Infective diarrhoea: 
Antibiotics are recommended only in patients who are severely affected by bacterial 
infection and show signs of systemic involvement, including high fever and 
prostration. Antibiotics like oxytetracycline, amoxicillin, tetracycline, ampicillin, 
chloramphenicol, doxycycline, metranidazole are given to treat diarrhoea. It is not 
uncommon for Salmonella to become resistant to commonly used antimicrobial 
agents such as amoxicillin. Campylobacter is sensitive to erythromycin and 
tetracycline, while ciprofloxacin is effective against both organisms [13]. 
Nitazoxanide has been shown to be effective against infection with G. lamblia and 
Cryptosporidium parvum in children with diarrhoea [12]. But they have their own 
merits and demerits. Antibiotics upset the normal intestinal flora. Nowadays, 
treatment with antibiotics is not successful because of the development of multi drug 
resistant strains. Many anti-diarrhoeal preparations have proved to be either 
ineffective or too powerful, resulting in serious complications or even death in some 
cases [28] 
For Drug induced diarrhoea: 
Initially dose and duration of the drug should be adjusted based on the requirement to 
check for reduction in diarrhoea. However, if diarrhoea persists even after 
modification of dose and duration, immediate drug withdrawal is recommended and 
adequate hydration is ensured. If diarrhoea persists even after withdrawal, it is 
important to exclude pseudomembranous colitis by performing a sigmoidoscopy and 
sending a stool for cytotoxin assay. Using antidiarrhoeal agents are not recommended 
as they delay the return of bacterial flora to normal [16].  
 
For diarrhoea due to fear and anxiety: 
Mainstay of treatment in diarrhoea due to fear and anxietyincludes oral corticosteroids 
such as prednisolone or intravenous hydrocortisone for severe disease and 5-
aminosalicylates. Immunosuppressant drugs will be given as second-line agents for 
resistant disease while nutritional therapy may also be incorporated based on 
treatment response[29]. 
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Despite of the presence of various class of therapies, present day diarrhoeal 
management in general and paediatric diarrhoeal management in particular remains 
incomplete. In most of the cases, antibiotic therapy was ineffective because of the 
delay in proper diagnosis and development of disease resistant strains.Moreover, most 
of the diarrhoea of viral origin is very difficult to manage due to lack of specific anti-
viral drugs and only fluid management is followed in such cases. Oral corticosteroids 
and immune suppressants cannot be administered in diarrhoea precipitated by fear and 
anxiety due to the toxicity associated with them. Hence, there is a definite need for 
alternative therapies in addressing the lacunas present in the current day management 
of paediatric diarrhoea. 
` 
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Preparation and standardization - Overview: 
The test drug Pañcatīpākkiṉi cūraṇam (PDC) was prepared by following 
traditional parameters and presence of major ingredients in this are determined using 
basic qualitative analysis. The PLIM standards were also measured in order to 
establish a standard for quality assessment of the drug.   
Background:  
The term PDC literally means a drug with five flames. This could possibly due to the 
fact that this drug formulation is composed of five ingredients: māṅkoṭṭai paruppu 
(kernel of Mangifera indica), kaṟivēppilai (leaves of Murraya koenigii), 
cuṇṭaivaraṟṟal (dried fruits of Solanum torvum), ventayam (Seeds of Trigonella 
foenum graecum) and omam (seeds of Carum copticum)[30] . There are few other 
formulations with the same name. For instance, in citta vaittiya tiraṭṭu, a formulation 
has been given under the same name PDC (from now it will be referred as PDC1) but 
with different ingredients: cukku,miḷaku,tippili,ēlam, cīrakam[31]. However, the 
therapeutic indications for both the formulations are different.  PDC is indicated for 
treatment of cītakkaḻiccal, peruṅkaḻiccal, vayiṟu iraiccaluṭaṉ kūṭiyakaḻiccal and 
vayiṟṟukkaṭuppu, whereas, PDC1 is indicated for Indigestion,mayakkam, porumal,  
atticuram, cilēttumanōy, uṣṇa nōy,cūlai, veṭṭai, mūla vāyvu. Moreover, there are few 
drugs which have the ingredients of PDC as major content along with other 
herbs.cuṇṭai vaṟṟal cūraṇam[31] is one among them, which includes nellivaṟṟal and 
mātuḷampaḻattōlalong withcuṇṭai vaṟṟal,kaṟivēppilai , māṅkoṭṭai paruppu, omam 
andventayam. However, its indications are very similar to the indications of PDC such 
as porumal, māntam, iraiccal, kaḻiccal, mūlam, aticāram, kirakaṇi. Another 
formulation in yūkimuṉivar vaittiya cintāmaṇi[32] indicates a curam prepared from 
Preparation and standardization 3 
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omam,cuṇṭai vaṟṟal, kaṟivēppilai, uppu, peruṅkāyam,cukku,miḷaku,tippili,for 
treatment of   kunma kirāṇi(a disease characterised by head ache, excessive sleep, 
rheum, intense thirst, giddiness, excessive sweat, burning sensation, abdominal 
distension with bloating). Furthermore, a herbo-metallic formulation indicated for 
karuppa kirāṇi[32] (a disease in pregnant women characterized by diarrhoea, stomach 
ache, weakness of upper and lower limbs, yellow eyes, excessive thirst and vomiting. 
These symptoms will prevail till the foetus gets aborted) in yūkimuṉivar vaittiya 
cintāmaṇi is found to have omam,cuṇṭai vaṟṟal,māṅkoṭṭai paruppu, tirikaṭuku, 
intuppu, kirāmpu, cātikkāy,cātipattiri,apiṉi, kāntam, liṅkam,naṟcīrakam, ēlam, 
lavaṅkakapaṭṭai, karuñcīrakam, ativiṭayamas main ingredients.  Though all these 
formulations were indicated for different symptoms and diseases, most of the diseases 
indicated are more or less related to gastro-intestinal tract and hyper peristalsis. Hence 
it can be concluded that the ingredients of PDC is specific for management for hyper 
peristalsis.  
Materials and methods: 
General protocol for preparation of any Siddha formulation involves the following 
steps: 
1. Collection of raw material 
2. Authentication of raw material 
2. Purification 
3. Preparation 
4. Authentication of final drug 
Even in this study the same protocol was espoused for the preparation of PDC. 
Collection of Raw materials: 
Māṅkoṭṭai paruppu and kaṟivēppilai were collected from R. Puthupalayam, 
Rasipuram, Namakkal district, Tamilnadu – 637402 during the month of November, 
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2018. cuṇṭaivaraṟṟal, ventayam and omam were purchased from raw drug stores in 
Palayamkottai, Tirunelveli, Tamilnadu – 627002.  
Authentication of Raw material: 
One of the major issues while researching the traditional medicine is the 
authentication of the raw materials. Even among the practitioners of traditional 
medicine, it is well accepted that authenticating the raw material in general and herbs 
in particular is not a straightforward task. Hence all the ingredients of PDC were 
initially identified by experienced traditional practitioner and authenticated by 
taxonomist in Government Siddha Medical College, Palayamkottai.  
Purification: 
As there is no specific purification methods for any of the ingredients of PDC in 
Siddha literature, all the ingredients of the PDC were shade dried and any adulteration 
in purchased drugs were removed manually.  
Characterization of PDC: 
TGA (Thermo-gravimetry analysis) was performed by placing 2-5 mg of sample in an 
alumina cup and heated at the rate of 10°C/min up to 1000°C in a nitrogen 
atmosphere with a flow rate of 100 ml/min using an SDT Q600 (TA Instruments, 
USA).  
Qualitative analysis: 
Presences of various chemicals in PDC are determined using following methods. 
1. Test for calcium - 2ml of the above prepared extract is taken in a clean test tube. 
To this add 2ml of 4% ammonium oxalate solution. 
2. Test for sulphate - 2ml of the extract is added to 5% barium chloride solution 
3. Test for chloride - The extract is treated with silver nitrate solution. 
4. Test for carbonate - The substance is treated with concentrated HC. 
5. Test for starch - The extract is added with weak iodine solution 
6. Test for ferric iron - The extract is acidified with glacial acetic acid and 
potassium ferro cyanide. 
7. Test for ferrous iron - The extract is treated with concentrated nitric acid and 
ammonium thiocyanate solution. 
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8. Test for phosphate - The extract is treated with ammonium molybdate and 
concentrated nitric acid 
9. Test for albumin - The extract is treated with esbach’s reagent 
10. Test for tannic acid - This extract is treated with ferric chloride. 
11. Test for unsaturation - Potassium permanganate solution is added to the extract. 
12. Test for the reducing sugar - 5ml of benedict’s qualitative solution is taken in a 
test tube and allowed to boil for 2 minutes and add 8-10 drops of the extract and 
again boil it for 2 minutes 
13. Test for amino acid - One or two drops of the extract is placed on a filter paper 
and dried well. After drying 1% ninydrin is sprayed over the same and dried it 
well. 
14. Test for zinc - The extract is treated with potassium ferro cyanide. 
PLIM parameters: 
Various analytical specifications were performed as per the Pharmacopoeial 
laboratory of Indian Medicine guidelines[33]  and the reference followed for analysis 
is tabulated below.  
\Table 3.1: Methods followed for PLIM parameters analysis 
S No Parameters Reference of test methods 
1 Appearance IP Vol-I, 1996, p7 
2 Total solids IP Vol-I, 2014, p277 
3 Total Ash IP Vol-I, 2014, p98 
4 Acid insoluble ash IP Vol-I, 2014, p98 
5 Loss on Drying at 105°C IP Vol-I, 2014, p162 
6 Carbohydrates Biochemical Methods, 
Sadasivam.S,2005,p8-9 
Results: 
The results of preparation and characterisation are given below 
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Figure 3.1: Representative images of raw materials used in preparation of PDC A)kaṟivēppilaiventayam  
B) omam C) ventayam D) cuṇṭai vaṟṟalE) māṅkoṭṭai paruppu 
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Preparation: 
All the 5 ingredients are taken in equal quantity and powdered together in a 
pulveriser. Initial and final weights of the materials are noted to calculate the wastage 
during the preparation process. Then the pulverised material is sieved to remove the 
large fibre particles. The weight of all the intermediate is tabulated in table 2.1. 
Table 3.2: Preparation of PDC (mass measurements) 
Weight of Raw material  20g + 20g + 20g + 20g + 20g = 100g 
Weight of the pulverised sample  92g 
Wastage  100-92 = 8 
Weight after sieving  80g 
Weight of thippi 12g 
 
Characterisation: 
TGA analysis of PDC is shown 
in figure 2.1. This shows that 
most of the substances in PDC 
are organic and maximum 
degradation happen around 400 
oC.  
Primary chemical analysis of 
PDC showed the presence of 
calcium, sulphate, chloride, 
starch, ferrous form of iron and amino acid. Few substances such as carbonate, ferric 
form of iron, phosphate, albumin, tannic acid, zinc and reducing sugar are absent in 
PDC. 
Table 3.3:Results of PLIM parameters in PDC 
S No Parameters Results 
1 Appearance Brown coloured powder 
2 Total solids 11.01%w/w 
3 Total Ash 5.167%w/w 
4 Acid insoluble ash 0.4241%w/w 
5 Loss on Drying at 105°C 3.582%w/w 
6 Carbohydrates 19.86%w/w 
Figure 3.2: Thermo gravimetric analysis of PDC 
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Discussion and Conclusion: 
PDC was successfully prepared by strictly following the traditional procedures. As, 
the  degradation percentage of PDC after heating up to 10000C, it’s very clear that 
few inorganic substances such as calcium, sodium, silica, iron etc., may be present in 
the prepared PDC. This was vouched by the qualitative analysis performed in PDC. 
The PLIM standard analysis parameters were established and this can be used for 
establishing standards in future and determination of shelf life. Although this work 
has showed some insight about the nature of PDC, there are still open questions that 
need to be addressed in the future. Primarily the synergistic activity ofall the five 
plants together need to be established. Besides, the rationale behind the exact choice 
of the plant for their action needs clearer understanding.  
 
` 
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Pre-Clinical experiments on PDC - Overview: 
Preparation and characterization of Pañcatīpākkiṉi cūraṇam (PDC) was discussed 
in the previous chapter. This chapter involves the pre-clinical assessment of the 
activity and safety of PDC in-vitro and in-vivo. Initially, the anti-microbial activity of 
PDC in various bacterial strains was performed and its minimum inhibitory 
concentration was established. Then the safety of PDC was evaluated using standard 
animal models with respect to OECD guidelines. After that, the anti-diarrhoeal 
activity of the PDC is determined using castor oil induced diarrhoeal model and 
charcoal meal transit time test in wistar rats.   
Background:  
Though the use of animals for drug research is not appreciated by all medical systems, 
it was widely believed to be the most reliable method to demonstrate the quality of the 
candidate drug[34]. Almost all the Western Bio-medicine (WBM) drugs do have the 
detail documentation of their pharmacological and toxicological nature tested in 
animal species. Though Siddha medical system does have some traditional quality 
control methods/tests to ensure the quality of the prepared traditional drug, they do 
not have any detailed classical texts dealing with animal experiments. This is 
considered to be one of the major hurdles in global acceptance of Siddha drugs by the 
scientific and medical community. So, in the past few years various Siddha 
researchers have involved themselves in experimentation of Siddha drugs in animal 
species[35-37]. However, most of these experiments have not produced convincing 
results as these experimental procedures were primarily designed for WBM drugs that 
completely differ from Siddha drugs in many aspects. Siddha medical system has a 
Pre-Clinical experiments on PDC 4 
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personalized, multi-factorial and holistic approach. Each Siddha formulation in 
general and PDC in particular is a composition of many molecules with multiple 
targets as opposed to single molecule and single target strategy of WBM. Moreover, 
all the Siddha formulations are administered with suitable vehicles like honey, ghee 
and butter that will influence the therapeutic/toxic effect through the various 
molecules present in them[8]. These concepts of usage of same drug with vehicles for 
different disorders do not exist in WBM system. Furthermore, most of the Siddha 
formulations were administered with strict dietary restrictions depending on the 
nature of the disease and drug ingredients. So, all these factors will have a synergistic 
effect in the pharmacological/toxicological nature of Siddha formulation.Apart from 
these basic differences, most of the Siddha formulations will have a history of its 
clinical use for centauries in humans and the purpose of the pre-clinical study is to 
strengthen/document the already know safety/activity of the drug by demonstrating in 
animals. But in WBM, the candidate drug will be mostly a new chemical entity and 
the major objective of the pre-clinical study will be to evaluate any toxic effects in 
animals. Hence the experimental protocols of WBM should be manipulated in such a 
way that it addresses all these extra requirements of Siddha drugs. Considering all 
these limitations, the present study was designed to understand the following. 
1. Anti-microbial activity 
2. Safety 
a. Acute toxicity study 
b. Sub-acute toxicity study 
3. Efficacy 
a. Anti-diarrhoeal activity 
b. Anti-hyper-peristaltic activity  
Materials and Methods: 
Anti-microbial activity: 
Mullen-Hinton agar was used to for the estimation of minimum inhibitory 
concentration of PDC against various bacterial strains. The components of medium 
are given below   
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Components of medium: 
1. Beef extract – 300g/L 
2. Agar – 17g/L 
3. Starch – 1.5g/L 
4. Caesin hydropyxalate – 17.5 g/L 
5. Distilled water – 1000mL 
6. pH – 7.6  
Briefly, after preparing the agar plates, the organism was streaked on the medium and 
the test drug was loaded using disc method with the concentration of 4mg/ml and 
amikacin was used as the control. The plates were inspected after incubation at 370C 
for overnight and zone of inhibition was observed. 
Animal Experiments: 
Adult Wistar rats (6-8 weeks) of both sexes, procured from the Central Animal 
Facility, Kalasalingam University, were used for this study. The animals were kept at 
22±2 °C with a 12 h light/dark cycle, with free access to standard rat pellet diet 
(Hindustan Lever, India) and water ad libitum. The experimental protocols were 
performed after obtaining the necessary approval (CPCSEA approval number: 
AKCP/IAEC/95/2018-19) from the Institutional Animal Ethical Committee (IAEC) 
of Kalasalingam University. 
Dose concentration: 
As the human therapeutic dose of PDC is already established in the Siddha texts (250 
mg/dose) for normal adult with 3 times a day, animal equivalent dose was calculated 
using allometric dose translations[38]. Considering the weight of a normal adult as 
60kg, animal therapeutic equivalent was calculated as 
𝐴𝑛𝑖𝑚𝑎𝑙𝑒 𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑑𝑜𝑠𝑒(𝑟𝑎𝑡) = 𝐻𝑢𝑚𝑎𝑛𝑑𝑜𝑠𝑒 ×
𝐻𝑢𝑚𝑎𝑛𝐾𝑚
𝐴𝑛𝑖𝑚𝑎𝑙𝐾𝑚
 
𝐴𝑛𝑖𝑚𝑎𝑙 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑑𝑜𝑠𝑒(𝑟𝑎𝑡) = 12.5 ×
37
6
= 77.08 𝑚𝑔 𝑑𝑎𝑦⁄  
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Acute Oral Toxicity Study: 
This study was performed in compliance with OECD 425 (Up and Down method) 
guidelines[39].  Female rats were fed with 2000mg/kg of test substance and observed 
individually at least once during the first 30 minutes after dosing, periodically during 
the first 24 hours (with special attention given during the first 4 hours), and daily 
thereafter, for a total of 14 days, except where they need to be removed from the 
study and humanely sacrificed for animal welfare reasons or are found dead. Body 
weight was measured once in a week and feed consumption was measured daily. 
Animals were sacrificed at day 14 and gross pathology, if any were noted and taken 
for further investigation.  
28-days repeated oral toxicity: 
This study was performed in compliance with OECD 407 (repeated dose 28-day oral 
toxicity) guidelines[40].  Animals were totally divided into 4 groups (Normal control, 
low dose, medium dose, high dose) with 6 animals (3male and 3female) in each 
group. Normal control animals were administered only with distilled water. Low 
(therapeutic dose), medium (10 x therapeutic dose) and high (100 x therapeutic dose) 
drug treated groups were administered with respective concentrations of PDC 
dispersed in cow’s curd. The drug was administered for a period of 28 days orally 
using oral gavage tube. All the animals were sacrificed after 28 days and required 
biological samples were collected for further analysis. Body weight changes were 
noted once in a week and feed consumption was noted daily.Animal equivalent 
therapeutic dose was fixed as low dose. Medium and high dose were fixed as 10 times 
and 100 times that of the low dose respectively.  
Hematology and Biochemical analysis: 
About 1mL of blood samples were collectedfrom all the animals on 29th day from 
retro-orbital plexus before sacrifice. 
Hematology analysis was performed in whole blood using Haematology analyser. 
The serum was separated by allowing the remaining blood sample to coagulate at 
room temperature followed by centrifugation at 605rcf for 10 minutes. Biochemical 
analysis was performed in this serum using A 15 auto analyzer. 
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Histopathology analysis: 
After sacrifice, the specific organs were isolated, washed with cold saline, weighed 
and finally fixed in 10% buffered formalin solution for histopathological studies. The 
fixed tissues were embedded in paraffin and the sections were cut in 3-5μm slices and 
were stained using haematoxylin and eosin. The stained tissues were observed under 
light microscope. The scoring was given to the pathological features seen in the slide 
as 0 for normal, 1 for minimal, 2 for mild, 3 for  moderate, and 4 for marked and 5 for 
severe. 
Castor Oil-Induced Diarrhea in rats: 
This test was done based on the method used by Sunday A. Ejehet al[41]. 24 rats were 
divided in to 4 groups: Disease control, Standard Control, Low dose and High dose, 
with 6 animals in each group and placed in separate cages. The drug administration 
was performed as per the descriptions in table 4.1. After the over-night fasting, the 
first group received distilled water (10ml/kg) and the second group received 
loperamide (3mg/kg), serving as negative control (NC) and positive controls (PC), 
respectively. Groups 3&4 received therapeutic dose and two times the therapeutic 
dose of PDC, respectively. After one hour, all the animalsreceived 0.5ml/animal of 
castor oil orally. The severity of diarrhea was assessed for 4 hours. The mean total 
number of feces (dry and wet diarrheal droppings) was determined and compared 
with the negative control group. 
Table 4.1:Study plan for Castor Oil-Induced diarrhoea in rats 
Groups No. of animals Treatment protocol 
Disease control 5 Distilled water (10mL/kg)   
Standard control 5 Loperamide (3mg/kg)  
Low dose 5 77.08mg/kg of PDC    
High dose 5 154.16mg/kg of test drug  
The percentage inhibition of total defecation and the percentage inhibition of 
diarrheawere calculated using:  
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% of inhibition of defecation
=
Total number of feaces in N. C − total number of feces in treated group
Total number of feces in N. C
×  100 
 
 
 
%  inhibition of diarrhoea
=
Total number of diarrhoeal feaces in N. C − total number of diarrhoeal feces in treated group
Total number of diarrhoeal feces in N. C
×  100 
Note: The feces which are not in proper pellet form due to more amount of water in it 
are considered as diarrhoeal feces. 
Anti-hyper peristaltic activity: 
This test was done by determining the influence of PDC in Intestinal transit timebased 
on the method described by [42] in rats. In brief, 25 rats were divided into five 
groups: Disease control, Standard Control, Low dose, Medium dose and High dose 
with 5 animals in each group and placed in separate cages. The drug administration 
was performed as per the descriptions in table. 4.2. One hour after treatment with 
respective doses of drugs, diarrhoea will be induced by oral administration of 2 ml 
castor oil in each animal. Then, all the animals will be ingested with 1 ml/kg (p.o) of 
standard charcoal meal (10 % suspension in 5% tragacanth powder). All of the 
animals in each treatment group were sacrificed 20 min after administration of the 
charcoal meal and their small intestine were immediately isolated. 
Table 4.2: Study plan for anti-peristaltic activity in rats 
Groups 
 
No. of 
animals 
Treatment protocol 
Disease control 5 2 ml of castor oil, 1 hour after study initiation   
Standard control 5 Loperamide at the beginning of the study + 2 ml of castor oil, 1 
hour after study initiation   
Low dose 5 Low dose of test drug at the beginning of the study +  2 ml of 
castor oil, 1 hour after study initiation   
Medium dose 5 Medium dose of test drug at the beginning of the study + 2 ml of 
castor oil, 1 hour after study initiation   
High dose 5 High dose of test drug at the beginning of the study +  2 ml of 
castor oil, 1 hour after study initiation   
 
The travelled distance of the charcoal plug from pylorus to caecum as the peristaltic 
index (PI) was determined and expressed as a percentage of the total length of the 
small intestine. 
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Statistical analysis: 
All the results are expressed as mean ± SD (n= 8-10). One way ANOVA, followed by 
Dunnett’s post hoc test was performed to show the significance of the test results. 
p<0.05 was considered to be statistically significant 
Results: 
Anti-microbial activity: 
The results of anti-microbial activity of PDC is shown in table 4.3 
Table 4.3: Anti-microbial effect of PDC 
Organism Sensitivity Zone of drug Zone of control 
Klebsiella pneumoniae Resistant - 16mm (Amikacin) 
Streptococcus pneumoniae Sensitive 16mm 18mm (Amikacin) 
Pseudomonas aeruginosa Resistant - 18mm (Erythromycin) 
Staphylococcus aureus Resistant - 18mm (Erythromycin) 
 
 
Figure 4.1: Representative image of anti-microbial activity study 
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Acute toxicity study: 
No significant change in feed and water consumption was noted in any of the groups. 
A gradual increase in body weight was observed from day 1 to 14 in all the animals.  
No mortality was observed throughout the study. Gross observation of the soft tissues 
after sacrifice did not show any significant pathological changes after 14 days[36] 
28-days repeated oral toxicity: 
Cage side observations: 
No significant change in feed and water consumption was noted in any of the groups. 
A gradual increase in body weight was observed from day 1 to 28 in all the groups.  
No mortality was observed throughout the study in animals of any group.  
 
Figure 4.2: Body weight changes in animals of PDC treated groups compared with 
normal control 
Gross Pathology: 
Gross observation of the soft tissues did not show any significant pathological 
changes at the time of sacrifice. 
Biochemical parameters: 
The biochemical and haematological parameters of all the test animals were measured 
at the end of experiment and the results are depicted below. 
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Figure 4.3: Changes in RBC levels of PDC treated animals compared with normal 
control 
There is no significant difference between the level of RBCs in low dose, medium 
dose and high dose PDC treated groups compared with normal control. 
 
Figure 4.4: Changes in haemoglobin levels of PDC treated animals compared with normal 
control 
There is no significant difference between the level of haemoglobin in low dose, 
medium dose and high dose PDC treated groups compared with normal control. 
 
 
Figure 4.5: Changes in WBC levels of PDC treated animals compared with normal control 
There is no significant difference between the level of WBCs in low dose, medium 
dose and high dose PDC treated groups compared with normal control. 
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Figure 4.6: Effect of PDC in levels of neutrophils, eosinophils, monocyte and lymphocyte 
There is no significant difference between the level of neutrophils, eosinophils, 
monocyte and lymphocytes in low dose, medium dose and high dose PDC treated 
groups compared with normal control. 
 
 
Figure 4.7: Changes in serum urea levels of PDC treated animals compared with normal control 
There is no significant difference between the level of serum urea in low dose, 
medium dose and high dose PDC treated groups compared with normal control. 
 
Figure 4.8: Changes in creatinine and total bilirubin levels of PDC treated animals compared with 
normal control 
There is no significant difference between the level of serum creatinine in low dose, 
medium dose and high dose PDC treated groups compared with normal control. 
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Figure 4.9: Changes in SGOT, SGPT and ALP levels of PDC treated animals 
compared with normal control 
\There is no significant difference between the level of SGOT, SGPT and ALP in low 
dose, medium dose and high dose PDC treated groups compared with normal control. 
Anti-diarrhoeal activity: 
There is a significant difference in standard control compared with disease control in 
time of onset of diarrhoea (shown in Figure 4.10). However, time of onset of 
diarrhoea in low dose and high dose group compared with disease control in not very 
significant. 
 
Figure 4.10: Effect of PDC in onset of diarrhoea in animals treated with 
castor oil 
There is a significant decrease in standard control compared with disease control in 
weight of stools (shown in Figure 4.11). However, no significant difference is found 
between stool weight of low dose and disease control. High dose shows almost 3 
times increase in stool weight compared with disease control. 
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Figure 4. 11: Effect of PDC in weight of stools in animals treated with castor oil 
There is a significant decrease in total number of feces in standard control and high 
dose group compared with disease control (shown in Figure 4.12). However, total 
number of feces in low dose group compared with disease control in not very 
significant. 
 
Figure 4. 12: Effect of PDC in total number of fecal output in animals treated with castor oil 
There is a significant decrease in total number of diarrhoeal feces in standard control, 
low dose and high dose group compared with disease control (shown in Figure 4. 13). 
 
Figure 4.13: Effect of PDC in total number of fecal output with diarrhoea in animals treated 
with castor oil 
The percentage of inhibition of diarrhoea was significantly higher in standard control, 
low dose and high dose treated groups (shown in figure 4.14). 
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Figure 4.14: Effect of PDC in percentage inhibition of diarrhoea in animals treated 
with castor oil 
The percentage of inhibition of defecation was significantly higher in standard 
control. However, low dose and high dose treated groups show a moderate inhibition 
in a dose dependent manner (shown in figure 4.15). 
 
Figure 4.15:Effect of PDC in percentage inhibition of diarrhoea in animals treated with castor oil 
Intestinal transit time estimation in Rats: 
 
Figure 4.16:Representative image of intestine isolated from rat after administration 
of charcoal meal 
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There is a significant difference between the distance travelled by charcoal meal in 
high dose group and standard control group (shown in figure 4.16 and Figure 4.17). 
However, no statistically significant difference was found in low dose and medium 
dose compared with disease control group. 
 
 
Figure 4.17: Effect of PDC in regulating the peristaltic movements 
Discussion: 
The primary objective of this study was to establish the safety profile of PDC on short 
term and long term oral administration. The single dose administration of 100 times 
the therapeutic dose of PDC did not show any significant change in cage side 
observations. Moreover, no mortality was observed in the animals for a period of 14 
days after oral administration. This clearly indicates that PDCis very safe at oral 
administration and do not produce any toxic symptom even at very high doses.  
After 28 days of drug administration, the absence of any notable cage side 
abnormalities, absence in body weight changes and absence of animal mortality 
indicates that oral administration of 100 times the therapeutic dose of PDC do not 
produce any lethal toxic effects.  
However, in order to understand non-lethal toxic effects, systemic analysis of the 
biochemical and haematological parameters are performed. Among the 7 
haematological parameters measured, no significant changes could be noted inany of 
the treated groups. Moreover,asno alterations in any liver functions parameters such 
as bilirubin, AST, ALT, ALP and triglycerides are noted, it is concluded that PDC did 
not have any toxic effect in liver.  
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In the intervention of diarrhoea, antimotility and antisecretory agents remain as the 
main agents used to decrease such patho-physiologic changes. Castor oil has been 
widely used for induction of diarrhoea in antidiarrheal activity studies because it 
releases ricinoleic acid, a metabolite that causes diarrhoea, upon metabolism in the 
gut [41]. Ricinoleic acid initiates diarrhoea via mechanisms such as irritation of GI 
mucosa, leading to the release of prostaglandin which stimulates gastrointestinal 
motility and electrolyte secretion, reducing electrolyte absorption from the intestine 
and colon; these are similar to the pathophysiologic processes resulting in diarrhoea. 
Therefore, the antidiarrheal activity of the plant might be due to the activities that 
oppose the actions of castor oil for induction of diarrhoea or pathophysiologic 
processes leading to diarrhoea. The PDC has been shown to decrease the intestinal 
fluid accumulation. This suggests that the PDC may decrease water and electrolyte 
secretion to the intestinal lumen while promoting their absorption, which in turn could 
decrease intestinal overload and distension, leading to a decrease in intestinal motility 
(giving a longer time for absorption) and water contents of the faecal drops and hence 
overall reduction in the total number of defecation instances and diarrheal drops in 
treated groups. This is consistent with the mechanism of action of loperamide for its 
antidiarrheal effect as presented in the literatures. In addition, PDC may have an 
anticholinergic activity and cause reduction in intestinal motility and secretion, which 
is in agreement with the action of atropine on the intestine. 
Conclusion: 
The World Health Organization suggests that traditional medicines have the potential 
to heal various diseases that western biomedicine is unable to cure. However, many 
formulations, which forms the core part of some Asian traditional medicines such as 
Siddha medicine, Ayurveda medicine and Chinese traditional medicine do not get 
global recognition due to repeated reports of toxicity associated with them [38]. In 
this work, PDC, an herbal drug of Siddha origin was tested for its toxicity in wistar 
rats. Animals were administered with 3 different doses (therapeutic dose, 10 X 
therapeutic doses and 100X therapeutic dose) of PDC and various haematological, 
biochemical and histopathology parameters were performed to understand the effect 
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of PDC. Apart from this the therapeutic effect of PDC was evaluated by its effect in 
reducing the diarrhoea and regulating the peristaltic movements. From all these 
analysis following conclusions were drawn 
1. No lethal effects were noted in oral administration of PDC from therapeutic 
dose to 100 times the therapeutic dose. 
2. No symptoms of toxicity were noted in oral administration of 
PDCfromtherapeutic dose to 100 times the therapeutic dose. 
3. Anti-diarrhoeal property of PDC was found to be more efficient at high doses.
` 
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Clinical features and management of āma kaḻiccal with PDC: 
The effect of pañcatīpākkiṉi cūraṇam (PDC) therapy on treatment of Āma KaḻIccal (AK) 
was studied clinically in 40 subjects of both sex aged between 1-12 years. Various 
causative factors such as infection, indigestion, fear, anxiety and teething were taken in to 
consideration. In addition, other influencing factors such as age, sex, geographical 
location, seasonal variation were also taken into account before analysis. This study 
showed PDC therapy was significantly effective in AK caused due to infection, 
indigestion and fear but not in teething. 
Background: 
A detailed study about AK is very few in contemporary literature. List of drugs 
previously studied for management of AK is shown in table 5.1. Briefly, Patturayan et al 
reported that Poṭutalai Camūlam was effective in 80% of the subjects affected by AK in 
2005. A year later, Kamalanathan et al., reported the effect of Ventaya Cūraṇam in 
subjects affected by AK. Cītapēti Cūraṇam is found to be clinically effective in 60% of 
the AK affected subjected treated by Naadimuthu et al.Cukku Poṭi and Mātuḷampiñcu 
Cūraṇam was reported to be significantly effective in management of bacillary and 
amoebic dysentery. Beatrice et al reported the effect of Oma chooranam in management 
of bacillary dysentery, spasmodic abdominal pain and rectal tenesmus and claimed that it 
help in maintenance of electrolytes and normal intestinal flora. However, in all these 
works, AK is considered analogous to bacillary dysentery and reported to be significantly 
effective against it though most of these reports were hand-wavy without any 
corroborating evidences. Quite antithetical to this, most of the Siddha texts describe AK 
Clinical features and management of  
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as specific inflammation and ulceration of the mucus living of the large intestine due to 
any reason resulting in phlegmatic evacuations in which the stool is mixed with mucus 
[7]. As these symptoms are seen in many type of enteritis other than bacillary dysentery, 
it is very clear that bacillary dysentery is not the best homolog for AK. Moreover, 
according to TVS Tamil medical dictionary, AK is the Tamil term for catarrhal enteritis. 
From the above discussions it can be indisputably concluded that AK represents enteritis 
of all origin and bacillary dysentery just is one among them. This implies that a detailed 
study on diseases precipitating with enteritis is essential to understand the nature of AK 
described in Siddha texts. In order to address this, AK was selected as the research topic 
and present study was designed carefully to have a complete contemporary understanding 
of AK. As more than eight Siddha formulations were previously known to be tested 
clinically for treatment of AK (at least for bacillary dysentery), a detailed literature search 
was performed across various Siddha classics to collect information about various class 
of medications  for general kaḻiccal initially followed by specific search for medications 
for AK. 
Treatment strategies for management of kaḻiccal in Siddha: 
Various classes of medications prescribed for kaḻiccal in Siddha literature is shown in 
table. 5.1. Cūraṇam, Lēkiyam, Cāṟu, Kaṟkam, Māttirai, Kuṭinīr and Ney were the most 
commonly used medications for the management of kaḻiccal. Though most of the drugs 
prescribed are of purely herbal origin, there was notable number of drugs of animal and 
metal origin too. Few mercury based medicines such as Liṅka Meḻuku, Liṅkatuvar 
Centūram, Caṇṭa mārutam were also prescribed for uncontrolled diarrhoea. This could be 
due to the well-known anti-microbial property of mercury based drugs.  Drugs such as 
Aṉṉapēti Centūram, which is iron based is also commonly used due to its well-
established anti-peristaltic effect. However, when it comes to paediatric cases most of the 
medications are of herbal origin and very few drugs are of mineral origin (Pāla Cañacīvi 
Māttirai). Apart from these lists of drugs shown in table 1.6 there are lot of medications 
that are listed in various Siddha drugs but were not in current use.  PDC is one among 
them and no research has been performed till date to evaluate the effect of its activity 
against AK.  
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Table 5. 1: Commonly used siddha drugs for management of adult and paediatric diarrhoea 
General Medications Paediatric medications 
Paṟpam 
 
 
 
1. Pavaḻa Paṟpam  
2. Nattai Paṟpam 
3. Muttu Paṟpam 
4. Nāka Paṟpam 
5. Palakaṟai Paṟpam 
6. Cilācattu Paṟpam 
Cūraṇam 
1. Kapitāṣṭaka cūraṇam (avbr) 
2. Tayircuṇṭi  Cūraṇam[43] 
3. Mātuḷṅkkōtuc Cūraṇam[43] 
4. Kācukaṭṭi Cūraṇam[43] 
5. Cuṇlai Vaṟṟal Cūraṇam [44] 
6. Panjadeepakni Cūraṇam[30] 
Lēkiyam 
1. Iñci Lēkiyam  
2. Cātikkāy Lēkiyam 
3. Vilvāti Lēkiyam 
Lēkiyam 1. Vaccira Kaṇṭi Lēkiyam [8] 
Centūram 
1. Aṉṉapēti Centūram  
2. Liṅkatuvar Centūram 
3. Caṇṭamārutam 
Ney 
1. Vaṭṭattiruppi Ney[30] 
2. Uppili Ney[8] 
3. Vēliparutti Ney[30] 
Maṇapāku 
1. Vilvāti  Maṇapāku 
2. Cemparutti Maṇapāku 
Kaṟkam 
1. Kuṉṟi Kaṟkam [45] 
2. Kīḻānelli Vēr Kaṟkam[8] 
Māttirai 
1. Kapāṭa Māttirai  
2. Vaccira Māttirai  
3. Cātikāy Māttirai 
Māttirai 
1. Ativiṭaya Māttirai  
2. Kapāṭa Māttirai 
3. Tāmarai Vaḷaiya Ēlātk Kuḷikai 
4. Vāḻaippottik Kuḷikai 
5. Pāla Cañacīvi Māttirai 
Kuṭinīr 
1. Tippiliyāti Kuṭinīr  
2. Maramañcaḷ Kuṭinīr  
3. Ativiṭaya Kuṭinīr 
Kuṭinīr 
1. Aṉṉak Kuṭinīr  
2. Mātuḷam Paḻattōl   
3. Maramañcaḷ 
Meḻuku 
1. Liṅka Meḻuku 
2. Cātikkāy Meḻuku 
Others 
1. Puḷiyārai Cāru[8] 
2. Paṭikaliṅkkatuvar [43] 
3. Āmaiyōṭṭu Paṟpam [43] 
Considering all these information, the present study was designed to evaluate the effect of 
PDC in treatment of subjects affected by AK.  List of drugs previously studied for 
management of AK is shown in table 1.6. Briefly, Patturayan et al reported that Poṭutalai 
Camūlam was effective in 80% of the subjects affected by AK in 2005. A year later, 
Kamalanathan et al., reported the effect of Ventaya Cūraṇam in subjects affected by AK. 
Cītapēti Cūraṇam is found to be clinically effective in 60% of the AK affected subjected 
treated by Naadimuthu et al. Cukku Poṭi and Mātuḷampiñcu Cūraṇam was reported to be 
significantly effective in management of bacillary and amoebic dysentery. 
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Table 5. 2: List of drugs previously studied for management of aama kaḻiccal 
Medicine Guide and Investigators Year 
Poṭutalai Camūlam Dr. R. Patturayan March 2005 
Ventaya Cūraṇam Dr. Kamalanathan & Dr. R. Patturayan March 2006 
Cītapēti Cūraṇam Dr. Naadimuthu & Dr. R. Patturayan September 2007 
Vilvāti Cūraṇam Dr. Gowsalya & Dr. N. Chandra Mohan September 2008 
Mātuḷampiñcu Cūraṇam Dr. K. Shyamala March 2009 
Cukku Poṭi Dr. D. K. Soundararajan April 2011 
Ōmac Cūraṇam Dr. A. Beatrice & Dr. K. Shyamala April 2012 
Cītapēti Cūraṇam Dr. K. Salma Ryhana & Dr. D. K. Soundararajan October 2015 
Beatrice et al reported the effect of Oma chooranam in management of bacillary 
dysentery, spasmodic abdominal pain and rectal tenesmus and claimed that it help in 
maintenance of electrolytes and normal intestinal flora. However, in all these works, AK 
is considered analogous to bacillary dysentery and reported to be significantly effective 
against it though most of these reports were hand wavy without any corroborating 
evidences. Quite antithetical to this, most of the Siddha texts describe AK as specific 
inflammation and ulceration of the mucus living of the large intestine due to any reason 
resulting in phlegmatic evacuations in which the stool is mixed with mucus[7]. As these 
symptoms are seen in many type of enteritis other than bacillary dysentery, it is very clear 
that bacillary dysentery is not the best homolog for AK. Moreover, according to TVS 
Tamil medical dictionary, AK is the Tamil term for catarrhal enteritis. From the above 
discussions it can be indisputably concluded that AK represents enteritis of all origin and 
bacillary dysentery just is one among them. This implies that a detailed study on diseases 
precipitating with enteritis is essential to understand the nature of AK described in Siddha 
texts. In order to address this, AK was selected as the research topic and present study 
was designed carefully to have a complete contemporary understanding of AK.   
Materials and methods: 
 The patients reporting to out-patient department of Kuzhanthai Maruthuvam will be 
screened for following parameters and will be included in the study. 
 Patient history - History of recent food intake, recent travel, recent antibiotic intake, 
recent infection and any other relevant history will be taken into consideration. 
 48 
 
Clinical features and management 
48 
 Physical Examination - All the subjects will be physically examined in the following 
order: Inspection, auscultation, percussion, palpation. 
 Investigation – The patients will be subjected to various blood investigations such as 
TC, DC, ESR & haemoglobin. Apart from that the stool examination will be 
performed to evaluate the presence of ova, cyst, and occult blood. 
The subject recruitments for the study will be performed based on the criteria given in 
table.5.3. 
Table 5. 3: Criteria followed for sample recruitment 
Drug Administration: 
Mode of administration – three times a day after food orally with cow’s curd (however, 
based on the requirement it will be administered up to six times a day). 
Dose - 250 mg /40 kg 
Assessment parameters: 
The prognosis of the subject after treatment will be described based on four categories: 
 General Criteria – age, sex, seasonal variation, geographical location and diet 
habits. 
 Cause – history of indigestion, infection, antibiotic intake, teething and fear. 
 Siddha Parameters - Uṭal tātukkaḷ, Uyir tātukkaḷ, Eṇvakait tērvu 
 Signs and symptoms – hyper peristalsis, abdominal pain, abdominal tenderness, 
dehydration, sore anus, vomiting and urinary output. 
 Nature of stools – frequency of diarrhea, presence of blood and mucus, smell, 
colour and flatulence. 
Inclusion Criteria Exclusion Criteria Withdrawal  criteria 
1. Children aged between 1-12 years of 
both sex 
2. Children with diarrhoea and any of 
the following symptoms (stools with 
blood and mucus, pyrexia, low pitch 
voice, loss of appetite, nausea and 
vomiting) 
1. Severe Dehydration 
2. Acute life threatening 
diseases 
3. Abdominal distension due 
to any other serious illness 
 
1. Patient turned unwilling to 
continue the course 
2. Occurrence of any serious 
illness 
3. Occurrence of any adverse 
drug reactions 
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General Criteria: 
Seasonal variation – Siddha classics describe the seasonal variation into six stages that 
are tabulated in table 5.4 and prognostic difference will be expressed based on that 
Table 5.4: Seasonal variations described in Tamill classics 
Geographical distribution - 
Siddha classics describe the 
geographical location into six that 
are tabulated in table 5.5 and 
prognostic difference will be 
expressed based on that. 
 
Table 5.5: Geographical distribution of Tirunelveli district with respect to Tamil classification 
Geographic
al location 
Description Geographical distribution in Tirunelveli district 
Kuṟiñci The mountain and hill areas The Western Ghats 
Mullai The forest region The Kalakkad and Mundanthurai forests 
Marutam The plains 
The river beds at Cheranmahadevi, Tirunelveli, 
Gangaikondan, Vallanad and Srivaikuntam 
Neytal Sea and seashore Koodankulam and uvari 
Pālai Sandy deserts Thisaiyanvilai, saattankulam, Udangudi 
 
Prognostic difference based on age, sex and diet habits will be assessed by using 
standard methods.  
Cause: 
Cause of the disease will be assessed based on 
1. Intake of any antibiotics within 3 days of disease progression, fear and teething  
2. Indigestion –will be determined based on last three days of food consumed 
and percussion. 
3. Infection –will be determined based on the past history of diarrhea within 3 
months, recent travel, and hygiene and stool investigation. 
Siddha Parameters 
This will be accessed based on three categories: 
 Tamil month Gregorian 
calendar 
Kārkālam āvaṇi, puraṭṭāci August – October 
Kūtirkālam aippaci, kārttikai October – December 
Muṉpaṉi  mārkaḻi, tai December – February 
Piṉpaṉi māci,paṅkuṉi February – April 
Iḷavēṉil cittirai,vaikāci April –June 
Mutuvēṉil āṭi, āṇi June –August 
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1. Uyir tātukkaḷ, - Vātam, Pittam, and Kapam will be analyzed based on the 
descriptions in table 5.3and 5.4 respectively  
2. Uṭal tātukkaḷ,-Cāram, Cennīr, Ūṇ, Koḻuppu, Eṉpu, Mūḷai and Cukkilamwill be 
analyzed based on the descriptions in table 5.8. 
Table 5.6: Disparity of Uyir tātukkaḷ (Vātam) in subjects affected by AK 
Uyir 
Tātukkaḷ 
(Vātam) 
Functions Relation with 
disease 
Pirāṇaṉ Digestion, inspiration and expiration Indigestion 
Apāṉaṉ Evacuation of urine and feces. Proper functions of anal spincters, 
expulsion of menstrual flow and sperm, ingested food extracts to 
respected places 
Loose stools, 
urinary retention 
Viyāṉaṉ Regulates voluntary and involuntary movements, helps in   sensory 
perceptions, absorption and utilization of digested food 
Loose stools, 
dyspnea 
Utāṉaṉ  Storage and release of absorbed food materials, responsible for 
speech, self-confidence, attitude, memory and skin tone. 
Vomiting, low 
pitched voice 
Camāṉāṉ Digestion, assimilation and prevents the aggravation of other vayus.    Indigestion  
Nākaṉ Opening and blinking of eyes, piloerection improves learning skills.  No relation 
Kūrman Ocular movements,  visual perception, yawning, lacrimal secretion  
Kirukaraṉ Salivary secretion, nasal secretion, hunger, concentration of  mind in 
particular thing, cough, sneezing 
Loss of appetite 
Tēvatattaṉ Responsible for ocular movements, laziness, anger, internal conflict, 
etc.   
 
Taṉañceyaṉ Performs its functions only after death  
Table 5.7:Disparity of Uyir tātukkaḷ (Pittam and Kapam) in subjects affected by AK 
Uyir Tātukkaḷ Functions Relation with disease 
Aṉaṟpittam helps in digestion  Indigestion 
Irañcakappittam Increase the quantity of blood and responsible for red 
colour, conversion of food extract into blood. 
 Anemia 
Cātakappittam Helps to achieve one’s desires with the help of mind, 
intellect and determination 
 
Ālōcakam Visual perception  
Pirācakam Gives complexion and shining  
Avalampakam Helps in respiration, cardiac functions and regulates 
other kabas  
Disparity in other Kabas   
Kilētakam Make the food particles soft  and assist in digestion Indigestion 
Pōtakam Sense of taste  
Taṟpakam Cooling and refreshing all organs  Burning sensation of eyes 
Cantikam Maintains joint mobility.  
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Table 5.8:Disparity of Udal tātukkaḷ (Pittam and 
Kapam) in subjects affected by AK 
Udal thathukkal Disparity seen  aamka kalichal 
Cāram Loss of appetite 
Cennīr Anemia 
Ūṇ No relation 
Koḻuppu No relation 
Eṉpu No relation 
Mūḷai No relation 
Cukkilam No relation 
 
Table 5.9: Eṇvakait tērvu analysis in subjects affected by AK 
 Parameters have to be considered Disparity in AK 
Sparicam Heat or coldness of the body, pain and skin 
nature. 
Hot(fever) 
Cold(dehydration) 
Nā colour of the tongue, local lesion 
(ulceration, redness), coating, deposition 
and dryness of the tongue. 
Pallor (anemia) 
niṟam Color of skin, conjunctiva, teeth, nail bud No relation 
moḻi speech and voice No relation 
viḻi Colour of eye (redness, pallor), tears, 
rheum 
Pallor (anemia) 
Malam  Loose stools 
Mūttiram Colour, odour, froth, frequency and 
quantity of urine 
Urinary retention 
Signs and symptoms: 
Prognostic difference with respect to sore anus, vomiting and urinary output will be 
assessed with the help of verbal communication with the subject. 
Hyper peristalsis – the subject will be auscultated and increase in peristaltic sounds 
above 30 /minute will be considered as hyperperistalsis and prognosis will be assessed 
based on that. 
Abdominal pain / tenderness – The abdomen will be palpated and the tenderness / pain 
in nine regions of abdomen will be noted for prognostic assessment. 
 Dehydration – The dehydration status of the patient will be assessed using the method 
described by Emmanuel Ademola et al and is given in table 5. 10. 
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Table 5.10: Dehydration scale described by Emmanuel Ademola et al. 
A score of 0 indicates no 
dehydration, 1-4 indicates 
mild to moderate 
dehydration and 5-8 
indicates severe 
dehydration 
 
Nature of stools: 
Frequency of diarrhoea, presence of blood and mucus, smell and colour will be 
considered for prognostic assessment. 
Flatulence – Abdominal flatulence will be assessed by percussion of the abdomen and 
will be considered for prognosis.  
Results: 
The clinical outcome of the effect of PDC in management of AKis measured in terms of 
three categories. They include 
1. General criterion 
2. Signs and symptoms 
3. Causative factors 
4. Nature of stools 
General criterion: 
The impact due to variation in 
age, sex, dietary habits, seasonal 
variation and geographical 
location in efficacy of PDC in 
subjects affected by AK were 
analysed under general criterion.  
Approximately 75% of male and 
female recovered within 8 days 
(Figure. 5.1). 6% of female did not 
 Score of 0 Score of  1 Score of  2 
General 
appearance 
Normal Thirsty, restless or 
lethargic but irritable 
when touched 
Drowsy, limp, 
cold, sweaty 
comatose 
Eyes Normal Slightly sunken Very sunken 
Mucus 
membrane 
Moist Sticky Dry 
Tears Tears Decreased tears Absent tears 
Male Female
46 44
38
3
8
13
8 6 6
1-5 days 6-8 days 9-10days 11-15 days above 15 unrecovered
Figure 5. 1: Impact of sex in effect of PDC in subjects 
affected by āma kaḻiccal; n = Male(24), Female(16) 
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recover during the course of treatment. No other significant changes were noted between 
male and female in recovery 
 
Figure 5.2:: Impact of age in effect of PDC among the subjects affected by āma kaḻiccal; 
n = Below 3 years (2), 3-5 years(18), 6-8 years(9), 9-10 years(8), 11-12 years(3) 
Significant number of subjects aged between 3-12 years recovered with 5 days 
(Figure. 5.2). However, 33% of subjects aged between 11-12 years took more than 15 
days to recover. Moreover, approximately 35% of 6-10 years children took 6-8 days for 
recovery. One child below 3 years did not recover during treatment. 
 
 
Figure 5.3: Impact of seasonal variation in effect of PDC in subjects affected by āma kaḻiccal; n = 
Ilavenil (5), mutuvēṉil (1), Kārkālam (3), Kūtirkālam (2), muṉpaṉi (13), piṉpaṉi(16) 
All the Subjects affected during mutuvēṉil, kārkālam and kūtirkālam recovered within 5 
days (shown in Figure.5.3). Majority of subjects affected during muṉpaṉi and piṉpaṉi 
recovered within 8 days. Significant number of subjects treated during iḷavēṉil, took more 
than 9 days to recover and 20% of subjects did not recover during the PDC therapy. 
Below 3 3-5 years 6-8 years 9-10 years 11-12 years
55.6
44.4
25
66.7
50
33.3
37.538.9
22.2
25
5.6
12.5
33.3
50
Age of the subject
1-5 days 6-8 days 9-10days 11-15 days above 15 unrecovered
Ilavenil Muthuvenil Kaarkalam Koothirkalam Munpani Pinpani
20
100 100 100
38.5
31.3
20
38.5
56.3
40
7.7 6.37.7 6.3
20
Seasonal variation
1-5 days 6-8 days 9-10days 11-15 days above 15 unrecovered
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Figure 5.4: Impact of geographical location in effect of PDC in subjects affected by āma 
kaḻiccal n = Kuṟiñci (2), Mullai (2), Marutam (35), Neytal (0), Pālai (1) 
1. Approximately 50% of subjects in kuṟiñci, mullai, marutam, neytal, pālai and 
Marutham recovered within 5 days ( figure 5.4). This implies that recovery was 
fast in subjects living in kuṟiñci and marutamtiṇai. Significant number of 
recoveries was noted within 6-8 days in kuṟiñci, mullai, marutam, pālai tiṇai. 
Delayed recovery is noted in more numbers in marutam and mullai. 
Among 40 patients only 3 were 
vegetarian, however all the 
vegetarian subjects recovered 
within 5 days (Figure. 5.1). 
Whereas, only 37.8% subjects 
consuming mixed diet recovered in 
1-5 days.Approximately 60% 
subjects took more than 6 days to 
recover. 2.7% subjects did not 
recover during the course of 
PDC therapy.  
Kurinji Mullai Marutham Neithal Palay
50 48.650 50
31.4
100
5.7
2.9 2.9
Geographical location
1-5 days 6-8 days 9-10days 11-15 days Above 15 Unrecovered
Mixed Vegetarian
37.8
100.0
40.5
8.1 8.1 2.72.7
1-5 days 6-8 days 9-10days
11-15 days Above 15 Unrecovered
Figure 5.5: Impact of dietary habits in effect  of PDC in  
subjects affected by āma kaḻiccal n = Mixed (37),  
Vegetarian (3) 
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Siddha Assessment: 
 
Figure 5.6: Effect PDC in normalisingPirāṇaṉ, Apāṉaṉ, Viyāṉaṉ, Utāṉaṉand 
Camāṉāṉamong the subjects affected by āma kaḻiccal n=Pirāṇaṉ(10), 
Apāṉaṉ(40), Viyāṉaṉ(40), Utāṉaṉ(40)and Camāṉāṉ(40) 
Among subjects affected by AK, disparity in seen in Pirāṇaṉ, Apāṉaṉ, Viyāṉaṉ, 
Utāṉaṉand Camāṉāṉ. However, Pirāṇaṉreverted back to normal in all the subjects 
within 8 days.Whereas, significantly Apāṉaṉ, Viyāṉaṉ, Utāṉaṉ, Camāṉāṉand 
Kirukaraṉwere revertedback to normal within 8 days in 80% of subjects but took more 
than 15 days in few subjects.  
 
Figure 5.7: Effect PDC in normalisingNākaṉ, Kūrman,  Kirukaraṉ,  
TēvatattaṉandTaṉañceyaṉ among the subjects affected by āma kaḻiccal 
n=Nākaṉ(0), Kūrman(0),  Kirukaraṉ(40),  Tēvatattaṉ(22)andTaṉañceyaṉ(0) 
 
In ubapranadhi vayukkal, kirukaran is affected among 40 subjects. 
 
Pirāṇaṉ Apāṉaṉ Viyāṉaṉ Utāṉaṉ Camāṉāṉ
60
45 45 45 45
40
35 35 35 35
10 10 10 10
5 5 5 5
2.5 2.5 2.5 2.52.5 2.5 2.5 2.5
1-5 days 6-8 days 9-10days 11-15 days above 15 unrecovered
Kirukaraṉ Tēvatattaṉ
45 45.5
35
31.8
10
13.6
5 4.5
2.5
4.5
2.5
0.0
1-5 days 6-8 days 9-10days 11-15 days above 15 unrecovered
Nākaṉ, Kūrman and Taṉañceyaṉ remain unaffected
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Figure 5.8:Effect PDC in normalising Aṉaṟpittam, Irañcakappittam, Cātakappittam, Ālōcakam and 
Pirācakam among the subjects affected by āma kaḻiccal n= Aṉaṟpittam(40), Irañcakappittam(9), 
Cātakappittam(0), Ālōcakam(0) and Pirācakam(40) 
 
Disparity of Aṉaṟpittam and Pirācakam were noted in all the subjects and significant 
recovery is seen within 8 days. Irañcakap pittam disparity is seen in approximately 25% 
of the subjects and most of the subjects recovered within 8 days. 
 
 
Figure 5.9: Effect PDC in normalising Avalampakam, Kilētakam, Pōtakam,  Taṟpakam and Cantikam 
among the subjects affected by āma kaḻiccal n = Avalampakam(40), Kilētakam(40), Pōtakam(0),  
Taṟpakam(40) and Cantikam(0) 
Disparity of Avalampakam, Kilētakamand Taṟpakam werenoted in all the subjects and 
significant recovery is seen within 8 days. 
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Figure 5.10: Effect of PDC in normalising Cāram, Cennīr, Ūṇ, Koḻuppu, Eṉpu, Mūḷai 
and Cukkilam among the subjects affected by āma kaḻiccal n = Cāram (40), 
Cennīr(9) , Ūṇ(0), Koḻuppu(0), Eṉpu(0), Mūḷai(0)and Cukkilam(0) 
Cāram and Cennīr was affected in significant number of subjects and majority of the 
subjects recovered within 8 days. 
 
 
Figure 5.11: Effectof  PDC in normalising the disparity in nāṭi 
 Most of the affected individual showed vātapittam and pittavāta nāṭi and most of the 
subjects recovered within 8 days. Among the 2 subjects with kapavātamnāṭi, one took 
more than 15 days to recover. One subject withpittavāta remains unrecovered 
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Figure 5.12: Effect of  PDC in normalising Sparicam, Nā, Niṟam, Moḻi, Viḻi, Malam and 
Mūttiram among the subjects affected by āma kaḻiccal n = Nā(9), Niṟam(0), Moḻi(0), Viḻi(9), 
Sparicam(0), Malam(40)andMūttiram(26) 
In Envagai thervugal, malam, Mūttiram, Nā, ViḻI were affected and remaining unaffected. 
 
Signs and symptoms: 
Among 40 subjects, 77% subjects recovered from abdominal pain within 8days. 
(Figure.4.6).However 3% took above 15 days to recover and 3% subjects did not recover 
during the course of PDC therapy. 
 
Figure 5.13: Effect PDC in reducing abdominal pain among the subjects affected by 
āma kaḻiccal n=35 (present), 5 (absent) 
Most of the subjects recovered from anal irritation, flatulence and vomiting within 8 days 
(Figure 5.15). However, considerable number of subjects took around 9-15 days to 
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recover from hyperperistalsis. One subject did not recover during the course of PDC 
therapy from hyperperistalsis and vomiting. 
 
Figure 5.14: Effect  of PDC in reducing the abdominal tenderness in subjects affected 
by āma kaḻiccal 
Most of the subjects with different types of abdominal tenderness recovered within 8 
days. However, few subjects with tenderness in umbilical, epigastric, hypochondrial and 
lumbar regions took more than 8 days to recover. One subject with umblical tenderness 
fail to recover. 
 
Figure 5.15:Effect of PDC reducing Sore anus, flatulence, hyperperistalsis and vomiting 
among the subjects affected by āma kaḻiccal n = Sore anus (23), flatulence (14), 
Hyperperistalsis (40), Vomiting (22) 
Significant percentage of subjects at various stages of dehydration recovered within 8 
days (Figure 5.16). However, one subject with moderate dehydration took around 15 days 
to recover and one subject did not recover during the course of PDC therapy from 
dehydration. 
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Figure 5.16: Effect of PDC in improving the dehydration status of subjects affected by 
āma kaḻiccal n= 23 (minimal), 13 (mild), 4 (moderate) 
Causative factors: 
Most of the subjects affected due to indigestion, infection, seasonal variation, fear and 
antibiotic intake recovered within 6-8 days. One among the three reported subjects with 
AKafter antibiotic intake took more than 15 days to recover. One infant with AK during 
teething did not recover with PDC therapy. 
 
Figure 5.17: Effect of PDC therapy on āma kaḻiccal with respect to the causative factor 
Nature of stools: 
Most of the stools were of green and yellow colour and bloody stools is found only in 4 
subjects. Apart from two subjects, all other subjects recovered within 15 days. 
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Figure 5.18: Effect of PDC in management of āma kaḻiccal with respect to colour of the 
stools. n = Brown, green, yellow, bloody 
Significant number of subjects with diarrhoea, foul smelling stools, mucus in stools and 
mucus with blood in stools recovered within 8 days (Figure 5.19). Considerable number 
of subjects took 9-15 days to recover from foul smelling and mucus containing stools. 
20% of subjects with blood and mucus in stools took more than 15 days to recover. 
 
 
Figure 5.19 : Effect of PDC in management of diarrhoea, diarrhoea after food, foul 
smell, mucus and mucus with blood in subjects affected by āma kaḻiccal 
Significant number of subjects with bowel movements of 1-4 times per day, 5-6 times per 
day and above 6 times per day recovered within 8 days (Figure. 5.20).  However, 
approximately 30% of subjects with bowel movements of 5-6 times per day took more 
than 10 days to recover. One subject with bowel movements of 4 times a day did not 
recover. 
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Figure 5.20: Effect of PDC in frequency of stools per day among subjects affected by āma 
kaḻiccal. n= 4 episodes (15), 5 episodes (12), 6 episodes(7), above 6 episodes (6). 
Most of the subjects with past history of diarrhoea within 2 months before present illness 
recovered within 8 days (Figure. 5.21). One subject with past history of diarrhoea before 
2 weeks took 15 days to recover. 
 
 
Figure 5.21: Effect of PDC in the treatment of āma kaḻiccal with respect to the past 
history of diarrhoea. 
Subjects treated within 5 days showed fast recovery within 8 days. (Figure. 4.15).One 
subject with disease duration more than 6 days took above 15 days to recover. In subjects 
with disease progression after consumption of protein diet, spicy food and cow’s milk, 
there is 100% recovery within 8 days (Figure. 5 .22). 
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Figure 5.22: Effect of PDC in treatment of subjects affected by āma kaḻiccal with 
respect to duration of the disease food (6) 
Significant number of subjects with disease progression after consuming fast food took around d 
9-15 days to recover. One subject with normal diet history did not recover during the course of 
PDC therapy. 
 
Figure 5.23: Effect of PDC in management of āma kaḻiccal with respect to recent food 
history .n=Protein (6), Cow’s milk(2), Fast food (7), Normal food(19), Spicy  
 
Figure 5.24:  Effect of PDC in maintaining urine output among subjects affected by āma kaḻiccal. 
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80% with decreased urinary output recovered within 8 days and 3.8 % remains did not 
recover during the course of study (Figure. 5.24). 
Discussion: 
Despite the high incidence of AK in male compared with female, recovery was faster in 
male. Effect of psychological stress related hormones would have played a major role in 
better effect of PDC in males. Our study also showed that PDC therapy was also effective 
in diarrhoea due to fear and anxiety. It is a well-established fact that psychological stress 
can modulate the gastrointestinal and immune systems through the hypothalamus-
pituitary-adrenal (HPA) axis. Huges et al showed that acute psychological stress was 
directly related to symptoms of gastrointestinal dysfunction. PDC is found to be more 
effective in children of 3-10 years and was not much better in age group below 3 years 
and above 11 years. This could possibly due to the underdeveloped HPA axis in children 
below 3 years and disturbed HPA axis from 11-17 years. As the effect of ingredients of 
PDC on HPA is not well established in literature, this study provides new information on 
the benefit of PDC (and its individual ingredients) therapy on HPA axis in young 
children. Few of the vātam, pittam and kapam subtypes are imbalanced in AK subjects 
but most of the imbalances were compared within 8 days. As mentioned in Siddha texts, 
our study demonstrated that 80% of AK cases were reported only during muṉpaṉi, 
piṉpaṉi during which pitta humour gets naturally aggravated. Moreover few cases 
reported during kārkālam, kūtirkālam and mutuvēṉil, in which pitta humour remains 
normal recovered within 5 days. This clearly shows that AK was primarily due to 
aggravated pittam, and initially the aggravated humour should be balanced before 
treatment. This also substantiate the statement Dr. Sampasivampillai in his dictionary 
which dictates the predisposing cause to this disease are the changing period from hot 
weather into the damper season of the monsoon. In pranathi vaayukal, the disparity is 
seen in pirāṇaṉ, apāṉaṉ, viyāṉaṉ, utāṉaṉand camāṉāṉ. It may be due to change in 
physiological function. One among the function of pranan is the digestion of food which 
is altered in loose stools. In apāṉaṉ, the normal function is expulsion of stool and urine 
and helps in contraction of anal sphincter which is affected in AK. Viyāṉaṉ which is 
paravukaal functions both in voluntary and involuntary muscles which also helps in 
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flexion and extension of organs. As utāṉaṉ is melnokkungaal, vomiting and low pitched 
voice indicates the disparity of utāṉaṉ. Loss of appetite among subjects indicates 
disparity in kirukaran. Though most of the cases of AK are reported from marutam 
region, it could not be concluded that AK is predominant in marutam as the study centre 
was primarily located in marutam and chances of affected subjects reporting from Neytal, 
Pālai, kuṟiñci, mullai will be relatively rare. Hence a multi-cantered trail is required to 
confirm this. Among the reported subjects only few subjects were vegetarians and they 
recovered within 5 days which shows the disease management was much easier in 
vegetarians compared with subjects in mixed food habits. 
As far as the cause is concerned, only T. V. Sambasivampillai, cite AK as Tamil 
description of catarrhal enteritis. Modern texts refer enteritis as a pathological condition 
with a decrease in the consistency of stools and an increase in the frequency of 
evacuations (typically more than 3 in 24 hours), with or without fever or vomiting. This 
can be caused due to various factors such as infection, indigestion, drugs, auto-immune 
disorders, fear and some normal physiological processes such as teething. Other 
secondary factors such as geographical location, seasonal variation, age, sex and dietary 
habits play an important role in regulating these factors in an indirect way. As 
descriptions of AK in Siddha texts were very similar to the symptoms of enteritis, all the 
above-mentioned factors were considered carefully in this study. The primary cause of 
enteritis due to infection among infants and children worldwide is viral gastroenteritis 
caused by rotavirus. Other causes include bacterial pathogens such as E.coli, Vibrio 
cholerae, Shigella, and Salmonella and protozoa such as Entamoeba histolytica, 
Cryptosporidium parvum and Giardia lambli. Seasonal change and immune status of the 
child play an important role in prognosis of the disease. In the present study, PDC 
therapy was found to be more effective in gastritis due to infection. Anti-microbial and 
anti-oxidant properties of   various extract of Mangifera indica (MI) kernel, Murraya 
koenigii (MK) [46, 47], Solanum torvum (ST) [48], Carum copticum (CC) and  
Trigonellum foenum graecum (TFG) is well established in literature. Sibanarayanan et 
al.reported that methanolic extract of CC, TFG andMI inhibited the growth of various 
Multiple Drug resistance strains (Enterococcus, Staphylococcus, Acinetobacter, 
Citrobacter, Enterobacter, E.coli, Klebsiella, Proteus and Pseudomonas) isolated from 
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urinary tract infections in a significant way. [49] Kabuki et al. reported antimicrobial 
activities of an ethanolic extract from MI kernels against 18 bacterial species including 
food- borne pathogens. These anti-bacterial activities were reported to be due to the 
presence of hydrolysable tannins in them. Furthermore, MK was reported for its anti-
tuberculosis effect [47], analgesic and anti-inflammatory property [50]. Methyl caffeate, 
a compound isolated from ST is found to have antimicrobial activity particularly against 
gram negative bacteria species (Salmonella, Pseudomonas, Proteus, Bacillus and 
Klebseilla) and few fungal species (Candida albicans and Aspergillus flavus)[48]. CC 
has antiviral activity against hepatitis C virus and Japanese encephalitis.[51]and found to 
inhibit the growth of Staphylococcus aureus Shigella flexneri and pseudomonas 
auerginosa..[52]. TFG  extract was able to prevent the proliferation of acanthameobiasis 
[53] and inhibits H pylori by enhancing alpha-amylase activity[54]. However, [55] 
Rachel O Mahony et al claim that only the TFG sprouts   were effective against H.pylori 
and not the TFG seeds. Methanolic fractions of TFG have anti-fungal activity against 
Botrytis cinerea, Fusarium graminearum, Alternaria sp., Pythium aphanidermatum, and 
Rhizoctinia solani. [56]. These reports vouch the significant effect of PDC therapy in 
cases of enteritis due to infections. As, PDC has ingredients which has anti-microbial 
sensitivity against broad group of bacteria, virus and protozoans, this can be used in 
management of all kind of infections leading to gastroenteritis. However, the synergistic 
effect of all these ingredients should be clinically evaluated for better understanding.  
In present study, the subjects treated with therapy within 5 days of onset of 
disease recovered within short period of time. However subjects treated 5 days after onset 
of disease took longer time to recover and this result was irrespective of the people with 
past history of diarrhoea within a period of 2, 3 months. This shows that PDC therapy is 
also very promising in management of gastritis due to indigestion.Apart from its anti-
microbial properties; ingredients of PDC also possess anti-inflammatory and anti-oxidant 
properties. Most of the patient were presented with abdominal pain and hyperperistalsis 
and significant number of patients were reported with sore anus, flatulence and vomiting. 
This could possibly due to the systemic inflammation of large intestine as described by 
various authors in siddha literature. Effect of PDC was very significant in addressing all 
these symptoms within 8 days. MI kernel extracts were also found to inhibit the 
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prostaglandin secretion and in turn will reduce the electrolyte permeability in gut. 
Aqueous extract ofST shows anti-inflammatory and analgesic activity by inhibition of 
prostaglandin. Effect of carbazole alkaloids isolated from MK viz., namely koenimbine 
and kurrayam were proved to be effective in decreasing the peristaltic movements in rats 
[57]. Arque-Ajeeb, a Unani formulation with CC as main ingredient was found to inhibit 
serotonin-induced diarrhoea in a dose dependent manner[58].TGF seed fractions were 
reported to protect against the gastric ulcer induced by ethanol in rats [59]. In addition, 
CC is able to increase the gastric acid secretion time and the amount of gastric acid. 
Moreover, it was shown that the CC can reduce the transit time of food in the digestive 
system of mice. Inhibitory effect of CC on the contractions of the digestive tract smooth 
muscle, especially the intestines, increased activities of digestive enzymes and bile 
secretion was reported, which support its effect on gastrointestinal tract.[45] . TFG 
enhances lipase and chymotrypsin action in liver and intestine of rats[60]. Moreover, MI 
kernel extract was reported to be a strong anti-oxidant which even has the capacity to 
neutralise the viper venom.This could be the primary reason for the enhanced activity of 
PDC therapy in gastritis with indigestion. Though, PDC therapy did not show any effect 
in enteritis during teething and moderate effect in enteritis due to anti-biotic intake, as the 
sample size was small, further studies are required to confirm this. 
Conclusion: 
Though the preclinical effects of various ingredients of PDC is already documented in 
literature, synergistic effect of PDC is not reported till date. This study is a step towards 
understanding the synergistic effects of all the ingredients of PDC in human subjects. As 
this study was performed with limited number of subjects, only little information could 
be made out of it. However, this could be taken as a lead and further trials should be 
performed with large scale to understand the activity of PDC in management of AK. PDC 
was found to be more effective inAK due to infection and indigestion. But the effect of 
PDC on AK due to antibiotic intake and physiological process such teething could not be 
established due to small sample size. Hence specific studies based on causative factors 
should be performed with large sample size to have a better understanding on PDC. 
Furthermore, long term studies should be performed to understand the influence of 
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season and geographical location in cause, progression and manifestation of AK. Once 
we have that information, we will have a complete contemporary understanding of PDC 
activity in humans.  
` 
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Summary and conclusion 
 
This study was primarily designed to understand the nature of AK described in Siddha 
literature through Siddha and biomedical parameters. Moreover, the effect of PDC in 
management of AK affected subjects is also evaluated. Briefly, the raw materials 
required for the preparation of PDC was collected from palayamkottai and 
authenticated by taxonomist in GSMCH, Palayamkottai. After authentication, the 
collected raw materials were sun dried, pulverised and mixed together. This is sieved 
in a cotton cloth (vasthirakayam) and very fine powder is obtained. The prepared drug 
was then characterised by various qualitative and instrumental analysis. Preliminary 
analysis showed the presence of calcium, sulphate, chloride, starch, ferrous form of 
iron and amino acid and absence of carbonate, ferric form of iron, phosphate, 
albumin, tannic acid, zinc and reducing sugar. The standardisation parameters were 
determined as per PLIM guidelines. Degradation temperature of PDC was found to be 
around 350- 400 oC. After characterisation, the acute toxicity of the drug was assessed 
in rats as per OECD 425 guidelines and was found to be safe upto 2000mg /kg body 
weight. With this information from the acute toxicity study, a 28 day repeated dose 
toxicity was performed and no observable toxicity is noted up to 100 times the 
therapeutic equivalent dose indicated for humans in Siddha texts. Preliminary 
antimicrobial activity study on Streptococcus pneumonia, Pseudomonas aeruginosa, 
Staphylococcus aureus and Klebsiella pneumoniae reveals that PDC was effective 
only against Straptococcus pneumoniae. Any subjects reporting with mucoid stools or 
stools with blood and mucus were included in the study.  Clinically, AK was 
predominant during the month of December to April (muṉpaṉi, piṉpaṉ) and the 
prevalence in vegetarian subjects is very low. This study revealed that PDC was 
Summary and conclusion  
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significantly effective in AK due to infection and indigestion. However, the effect of 
PDC on AK due to antibiotic intake and physiological process such teething could not 
be established due to small sample size. Hence specific studies based on causative 
factors should be performed with large sample size to have a better understanding on 
PDC. Furthermore, long term studies should be performed to understand the influence 
of season and geographical location in cause, progression and manifestation of AK. 
Once we have that information, we will have a complete contemporary understanding 
of PDC activity in subjects affected by AK. 
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32. yūki muṉivar vaittiya cintāmaṇi, ed. rā.tiyākarācaṉ. 1896, chennai: indian 
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List of transliterated words 
Transliterated form Tamil form 
 ēlam Vyk; 
 karuñcīrakam fUQ;rPufk; 
 lavaṅkakapaṭṭai  ytq;fgl;il 
Āmai Mik 
Āmaiyōṭṭu Paṟpam  MikNahl;L gw;gk;  
ĀmakkaḻIccal Mkf; fopr;ry; 
Aṉṉak Kuṭinīr  md;d FbePh; 
Aṉṉapēti Centūram  md;dNgjp nre;J}uk; 
Aṉupava Vaittiya Tēva Rakaciyam mDgt itj;jpa Njt ufrpak 
Aṉupava Vaittiya Tēva Rakaciyam mDgt itj;jpa Njt ufrpak; 
Apiṉi mgpdp 
Arttarā Kirāṇi  mh;j;ju fpuhzp 
Aticāra   mjprhu 
Aticāra Tōṭam mjprhu Njhlk; 
Ativiṭaya Kuṭinīr mjptpla FbePh; 
Ativiṭayam mjptplak; 
Ātmaraṭcāmirtam Eṉum Vaittiya Cāracaṅkirakam Mj;kuf;\hkph;jk; vd;Dk; itj;jpa 
rhurq;fpufk; 
Calak ryf; 
Caṅkarak  rq;fhuf; 
Caṅkirakak Kirāṇi rq;fpuhf; fpuhzp 
Caṉṉipāta Aticāram  rd;dpghj mjprhuk; 
Caṇṭamārutam rz;lkhUjk; 
Carapēntirar Vaittiya Muṟaikaḷ ruNge;jpuh; itj;jpa Kiwfs; 
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Cātikkāy rhjpf;fha; 
Cātikkāy Lēkiyam rhjpf;fha; Nyfpak; 
Cātikkāy Meḻuku rhjpf;fha; nkOF 
Cātipattiri rhjpgj;jphp 
Cemparutti Maṇapāku nrk;gUj;jp kzg;ghF 
Ceriyāppaṭuvaṉ  nrhpahg;gLtd; 
Cilācattu Paṟpam rpyhrj;J gw;gk; 
Cilēttuma Aticāram  rpNyj;Jk mjprhuk; 
Cilēttuma Kirāṇi   RpNyj;Jk fpuhzp 
Cītak  rPjf; 
Cītapēti Cūraṇam rPjNgjp #uzk; 
Cītapēti Cūraṇam rPjNgjp #uzk; 
Cōpak Nfhgf; 
Cukku Poṭi Rf;F nghb 
cūkkuma uṭal #f;Fk cly; 
Cuḻimāntam   Ropkhjk; 
Cuṇlai Vaṟṟal Cūraṇam  Rz;iltw;wy; #uzk; 
Cura  Ru 
Cura Aticāram Ru mjprhuk; 
Iñci Lēkiyam   ,Q;rp Nyfpak; 
Intuppu ,e;Jg;G 
Irai  ,iw 
Iraimāntam   ,iukhjk; 
Īraṟpaṭuvaṉ  <uw;gLtd; 
Irattam  uj;jk; 
Kācukaṭṭi Cūraṇam fha;r;Rf;fl;b #uzk; 
Kaṇa  fz 
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Kaṇai  fiz 
Kāntam fhe;jk;  
Kapam  fgk; 
Kapāṭa Māttirai  fghl khj;jpiu 
Kapitāṣṭaka cūraṇam   fgpl;lh\;jf #uzk; 
Karppa Kirāṇi fUg;gf; fpuhzp 
Kaṭuppu   fLg;G 
KaṭuppukkaḻIccal fLg;Gf; fopr;ry; 
Kīḻānelli Vēr Kaṟkam fPohney;yp Nth; fw;fk; 
Kirāmpu fpuhk;G  
Kirāṇi fpuhzp 
Kōpāla Paṉikkar Ācāṉ Pāla Vākaṭam Nfhghy gdpf;fh; Mrhd; ghy thflk;  
Kuṉma Kirāṇi  Fd;k fpuhzp 
Kuṉṟi Kaṟkam  Fd;wp fw;fk; 
kuru-cīṭaṉ  FU rpj;jd; 
Liṅka Meḻuku ypq;f nkOF 
Liṅkatuvar  ypq;fJth; 
Mānta  khj 
Manta Aticāram  khe;j mjprhuk; 
Maramañcaḷ Kuṭinīr  kukQ;rs; FbePh; 
Matalai Noy 2 kjiy  
Mātuḷam Paḻattōl   khJsk; goj;Njhy; 
Mātuḷampiñcu Cūraṇam khJsk;gpQ;R #uzk; 
Mūlakkotippu   %yf;nfhjpg;G 
Mūlavāyu Kirāṇi  %ythA fpuhzp 
Muttu Paṟpam Kj;J gw;gk; 
Nāka Paṟpam ehf gw;gk; 
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Naṟcīrakam ew;rPufk; 
Nattai Paṟpam ej;ij gw;gk; 
Niṇa epz 
NiṇakkaḻIccal epzf;fopr;ry; 
Nīrpaṭuvaṉ  ePh;gLtd; 
Nīrppāṭu  ePh;g;ghL 
Ōmac Cūraṇam Xkr; #uzk; 
Oṭṭu Kirāṇi  Xl;L fpuhzp 
Paccilai   gr;rpiy 
Pāl  ghy; 
Pal Muḷaikkum Pōtu Kaḻiccal   gy; Kisf;Fk;NghJ fopr;ry; 
Pāla Cañacīvi Māttirai ghyrQ;rPtp khj;jpiu 
Pāla Vākaṭa ghy thflk; 
Palakaṟai Paṟpam gyfiu gw;gk; 
Panjadeepakni Cūraṇam gQ;rjPghf;fpdp #uzk; 
Paṭikaliṅkkatuvar  gbfypq;fJth; 
Pavaḻa Paṟpam  gts gw;gk; 
Payam Aticāram  gak; mjprhuk; 
PeruṅkaḻIccal ngUq;fopr;ry; 
Peruṅkāyam ngUq;fhak; 
Piḷḷai Piṇi Maruttuvam gps;is gpzp kUj;Jtk; 
Piraḷi  gpusp 
pirāṉaṉ Gpuhzd; 
Pitta Aticāram  gpj;j mjprhuk; 
Pitta Kirāṇi  gpj;jf; fpuhzp 
Pittakapam gpj;jk; 
Pittam  gpj;jk; 
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Porumal   nghUky; 
Puḷiyārai Cāru  Gspahiu rhW 
Ratta  uj;j 
Ratta   ,uj;j 
Ratta Aticāram uj;j mjprhuk; 
Rattak  uj;jf; 
Rattapaṭuvaṉ  ,uj;jgLtd; 
stūla uṭal \;J}y cly; 
Tāmarai Vaḷaiya Ēlātk Kuḷikai jhkiu tisa Fspif 
Tayircuṇṭi  Cūraṇam  japh; Rz;b #uzk; 
Tippiliyāti Kuṭinīr  jpg;gpypahjp FbePh;  
Tirikaṭuku jphpfLF 
Tiritōca Aticāram  jphpNjhl mjprhuk; 
Tiritōca Kirāṇi jphpNjhl fpuhzp 
Toṅkal Kaḻiccal  njhq;fy; fopr;ry; 
Tonta Kirāṇi  njhe;j fpuhzp 
Tōṣā Aticāram Njh\ mjprhuk; 
Tōṭa   Njhl 
Tukka Aticāram Jf;f mjprhuk; 
Uppili Ney cg;gpyp nea; 
Uppu cg;G 
Uṣṇavāyu Kirāṇi  c\;zthA fpuhzp 
Vaccira Māttirai  tr;rpu khj;jpiu 
Vāḻaippottik Kuḷikai tisg;nghl;b Fspif 
Vānti  the;jp 
Varaḷ  tws; 
Vāta Aticāram  thj mjprhuk; 
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Vātak Kirāṇi Thjf; fpuhzp 
Vātak Kirāṇi thjf; fpuhzp 
Vātam  thjk; 
Vaṭṭattiruppi Ney tl;lj;jpUg;gp nea; 
Vayiṟṟuk tapw;Wf; 
Vayiṟṟukkaṭuppu  tapw;Wf;fLg;G 
Vayiṟṟukkotippu  tapw;Wf;nfhjpg;G 
Vayiṟṟuḷaivu tapw;WiyT 
Vāyuviṉāl Uṇṭākum Kirāṇi thAtpdhy; cz;lhFk; fpuhzp 
Vēliparutti Ney Ntypg;gUj;jp nea; 
Veḷḷuṭaik nty;Yilf; 
Ventaya Cūraṇam nte;ja #uzk; 
Ventaya Cūraṇam nte;ja #uzk; 
Veppu   ntg;G 
Vilvāti  Maṇapāku tpy;thjp kzg;ghF 
Vilvāti Cūraṇam tpy;thjp #uzk; 
Vilvāti Cūraṇam tpy;thjp #uzk; 
Vilvāti Lēkiyam tpy;thjp Nyfpak; 
Viṭā   tpl 
Yūkimuṉi Vaittiya Cintāmaṇi a+fpKdp itj;jpa rpe;jhkzp 
Yūkimuṉi Vaittiya Kāviyam a+fpKdp itj;jpa fhtpak; 
 ypq;fk; 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “            ”- 
A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS            Ṉ      ṆAM 
Form I-SCREENING & SELECTION PROFORMA 
S.I.No: ………….  OP/IP No: ……….  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:………….Reliability :  …………… 
INCLUSION  CRETERIA:     YES      NO   
 Age 1-12 years 
 Loose stools with blood or mucus                        
 Pyrexia 
 Low pithched voice 
 Loss of appetite 
 Nausea 
 Vomiting 
EXCLUSION CRITERIA: 
 Severe dehydration 
 Acute life threatening disease 
 Abdominal distension due to any other serious 
 illness 
 
 
 
Signature of Guide:     Signature of Principal Investigator:
  
 
 
 
Signature of HOD:  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “            ”. A 
PEADIATRIC DISORDER AND THE DRUG OF CHOICE IS 
             Ṉ      ṆAM 
FORM IA – HISTORY PROFORMA ON ENROLLMENT 
 
Patient id: OP/IP NO. VISIT DATE (___/____/_____) 
NAME :  
AGE:  
Gender:   MALE           FEMALE  Date Of Birth :( ____/____/_____)   
Fathers/Mother/Guardian name :  
Fathers Occupation:  
Fathers Monthly income:  
Religion:  
Socioeconomic status:  
Patient informant :  
 
 
 
 
 
 
 
 
1. Complaints and duration  
 
 
 
Postal Address  
 
 
Contact no: 
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2. Present illness  
History of past Illness 
History /Symptoms /Signs   Yes  No  if, Yes Details  
Any Similar Complaints      _____________ 
Bronchial Asthma       _____________ 
Dust Allergy        _____________ 
Hospitalization        _____________ 
Any Other         _____________ 
 
Family History       
Any hereditary familial Disease    Yes  No 
If yes, details………………………………………………………………………….. 
 
Immunization History  
Proper Immunization given   Yes  No …………………….. 
 
Food Habits:  
1. Veg   2. Non-Veg   3. Mixed  
 
General assessment                            Yes  No 
1. Picca 
2. Nail Biting 
3. Bowel Movements  
 
General Examination   Yes  No   
1. Pallor       
2. Jaundice        
3. Cyanosis         
4. Clubbing         
5. Pedal oedema        
6. Lymph adenopathy         
Vital signs:- 
1. Pulse rate / mint 
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2. Heart rate / mint 
3. Respiratory Rate / mint 
4. Temperature 
5. BP 
Anthropometry: 
Height 
Weight 
Head Circumference 
Chest Circumference 
Mid Arm Circumference 
CLINICAL EXAMINATION: 
    Normal            Affected 
 Cardio Vascular system:        
 Gastro intestinal system:        
 Musculo skeletal system:        
 Central nervous system:        
 Endocrine system:  
 
CLINICAL EXAMINATION OF SKIN: 
1. Site: 
………………………………………………………………………………… 
………………………………………………………………………………..... 
2. Colour: Normal    Reddish       Black           Pallor   
3. Itching: No                     Mild                 Moderate            Severe                   
 
EXAMINATION OF NAILS: 
1. Pallor:  Present              Absent               
2. Koilonychia: Present              Absent               
Nilam:  
        Mullai   Marutam  Neytal           Pāla  
  
    
  
  
  
  
  
    
    
  
  
 Annexure 17 
KaalaIyalbu 
 ārkālam   ūt rkālam                      Pa   
P  pa    iḷa    l                    m t     l 
Yaakai 
Vātam              Vātap ttam  Vātakapam 
Pittam              P tta ātam  Pittakapam 
Kapam               apa ātam  Kapapittam 
UyirThathukkal 
Vātam      Normal Affected  Remarks  
P rāṇa  
 pā a  
 tā a  
V  ā a  
 amā ā  
 āka  
 ūrman 
  r kara  
   atatta  
 a a    a  
Pittam             Normal    Affected  Remarks  
  a p ttam 
Irañcakappittam 
 ātakapp ttam 
Ālō akam  
P rā akam  
Kapam             Normal         Affected  Remarks  
Avalampakam 
  l takam 
Pōtakam 
Pōtakam 
Cantikam 
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Udalthathukkal    Normal    Affected  Remarks  
 āram  
  nnīr 
Ūṇ  
 o  pp  
  p  
 ūḷai 
Cukkilam 
Envagai Thervugal Normal Affected  Remarks  
 ā 
   am  
 o i  
V  i 
Sparicam 
Malam   Normal Affected  Remarks 
   am     
Nurai     
Iḷakal  
   kal 
Moothiram 
Neerkuri:  Normal Affected 
   am   
Eṭai   
Nurai   
            Maṇam 
             Eñcal 
Neikuri:   Normal Affected 
 Vātam  
 Pittam 
 Kapam  
 Others 
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Naadi: 
ThaniNadi 
 Vātam    Pittam   Kapam 
 
ThonthaNadi 
           Vātapittam           Pittavātam              Pittakapam       Kapapittam 
 
 
Sparism 
Diagnosis__________________________________ 
Admitted to trial : 1. Yes   2. No. 
if yes, S.No:  1IP   2.OP 
Diagnosis 
DRUGS ISSUED:______________ 
Date :________________________ 
Station _______________________ 
Date :       
Signature of the Guide   Signature of Principal Investigator: 
 
Signature of the HOD  
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 
FORM-IB:CASE SHEET PROFORMA-“             ” 
 
 
 
 
 
 
 
 
           
  Religion: 
       
       
       
 
 
 
 
 
 
 
     
  
I.P.No. : 
 
Bed. No. : 
 
Name of the Medical unit: 
 
Name : 
 
Age/Sex: 
 
Permanent Address: 
 
 
 
 
Temporary Address: 
PG-Pediatric Ward, Government Siddha 
Medical College & Hospital, 
Palayamkottai. 
Informant: 
 
Invesitgator: 
 
 
 
 
Nationality: 
 
Religion: 
 
Occupation(Parents): 
 
Income: 
 
Date of Admission: 
 
 
Date of  Discharge: 
 
 
Diagnosis: 
 
 
 
 
 
 
 
 
 
 
Medical Officer: 
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Complaints and duration : 
 
History of present illness : 
 
History of past illness : 
 
Personal History: 
 
Family History: 
Consanguinity    : 
 Ataxia     : 
 Blindness    : 
 CP     : 
 MR     : 
 Seizure    : 
 Movement disorder   : 
 Deafness    : 
Socio-Economic Status: 
Habits: 
 Bowel and micturation habit  : 
 Sleep     : 
 Enuresis    : 
 Thumb sucking   : 
 Nail biting    : 
 Pica     : 
Diet History : 
 Appetite    : 
 Types of diet    : 
Antenatal History : 
 Medication    : 
 Infection (STARCH)   : 
 Irradiation    : 
 Toxaemia    : 
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 Hemorrhage    :  
 Severe Anaemia   : 
 Eclampsia    : 
 H/o Decreased foetal Movements : 
 Maternal malnutrition   : 
 Maternal Diabetes Mellitus(DM) : 
 Maternal Hypertension  : 
Natal: 
 Breech presentation   : 
 Forceps / - C- Section   : 
 Home / Hospital   : 
 H/o prolonged labour   : 
Post Natal 
 Post partum Haemorrhage  : 
 Sepsis     : 
Neonatal History: 
 Birth Weight    : 
 Term / Pre term baby   : 
 Congenital malformations  : 
 Birth Asphyxia – APGAR – Score : 
 Neonatal convulsions   : 
 Kernicterus    : 
 Diarrhoea    : 
 Birth injury / Head injury / Activity of the child 
a) at birth   : 
b) after birth   : 
Time of cry after birth  : 
Resuscitation done or not  : 
(if done nature of resuscitation) 
Respiratory distress / cyanosis : 
Fever / altered sensorium  : 
Feeding after birth   : 
Lymphadenopathy   : 
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Developmental History : 
 
Immunization History : 
 
General Examination 
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
1. Consciousness : 
2. Decubitus  : 
3. Anemia   : 
4. Jaundice   : 
5. Cyanosis   : 
6. Clubbing   : 
7. Pedal oedema  : 
8. Lymphadenopathy   : 
9. Nourishment  : 
10. Skin changes   : 
11. Edema   : 
12.JVP   : 
13.Pulse Rate   : 
14.Heart Rate   : 
15.Respiratory Rate  : 
16.Temperature  : 
17.Blood Pressure  : 
18.Spine   : 
19.Skin   : 
Systemic Examination 
Cardio Vascular System : 
Respiratory System  : 
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Gastro Intestinal System : 
Genito Urinary System : 
Nervous System  : 
 Consciousness: 
 Temper Tantrum:  Sociable- Irritable - Playful 
 Memory  : 
 Orientation  : 
 Speech   : 
 Intelligence (I.Q) : 
 Handedness  : 
Cranial Nerve Examination: 
Motor System: 
 Power  : 
 Tone  : 
 Reflex  : 
 Grip  : 
 Gate  : 
Sensory Examination: 
 Superficial Sensation: 
  Touch  : 
  Pain  : 
  Temperature : 
 Deep Sensation: 
  Position sense : 
  Joint sense : 
  Vibration sense: 
 Cortical Sensation: 
Cerebellar Signs: 
 
Autonomic System: 
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Siddha Systems – Clinical Examination: 
Nilam 
        : 
Mullai: 
Marutam: 
Neytal: 
Pāla    : 
ParuvaKaalam 
Iḷa    l 
  t     l 
  ārkālam  
  ūt rkālam 
   Pa   
 P  Pa   
Uyirthathukal: 
Vatham 
P rāṇa   
 pā a  
 V  ā a  
  tā a   
  amā ā  
 āka  
  ūrman 
   r kara  
   atatta  
 a a    a  
Pitham 
  a p ttam 
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Irañcakappittam 
 ātakapp ttam 
 Ālō akam 
 P rā akam 
Kabam 
Avalampakam 
  l takam 
Pōtakam 
 a pakam 
Cantikam 
UdalKattugal 
 āram 
  nnīr   
Ūṇ 
 o  pp  
   p   
 ūḷai  
 Cukkilam 
EnvagaiThervugal 
Nāṭi  
Sparicam 
Nā 
Ni am 
 o i 
Vi i 
Malam 
 ūttiram 
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Neerkuri 
   am  
 Nurai 
Eṭai 
Maṇam 
Eñcal 
Neikuri 
Malakuri 
Nirami 
 Nura 
Iḷakal 
   kal 
Lab Investigations 
1. Blood 
TC  : 
DC : 
Hb  : 
ESR  : 
2. Urine 
Albumin  : 
Sugar   : 
Deposits  : 
3. Motion 
Ova   : 
Cyst  : 
Occult blood  : 
DIFFERNTIAL DIAGNOSIS  : 
PROGNOSIS    : 
MARUTHUVAMURAI   : 
ADVICE     : 
DAILY PROGRESS   : 
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Date 
 
Symptoms Medicine 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI  
 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY ON “            ”-A PEDIATRIC  
DISORDER AND THE DRUG OF CHOICE IS             Ṉ      ṆAM 
FORM - II&IIA  
CLINICAL ASSESMENT ON ENROLLMENT DURING AND AFTER TRIAL 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: ………… 
Date of Completion :………….   Informant: …………. Reliability :  …………… 
SIDDHA SYSTEM OF EXAMINATION 
 I.ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
1.NAADI: [PULSE PERCEPTION] 
2.SPARISAM: [SENSITIVITY] 
3.NAA:[TONGUE]  
4.NIRAM: [COMPLEXION] 
5.MOZHI: [VOICE] 
6.VIZHI: [EYES] (Lower palpebral conjunctiva) 
7.MALAM: [BOWEL HABITS / STOOLS] 
 1
st
Day 05thDay 7th Day 
Colour Dark/Yellow/ Red/ 
Pale 
Dark/Yellow/ Red/ 
Pale 
Dark/Yellow/ Red/ 
Pale 
Consistency Solid/ Semisolid/ 
Watery 
Solid/ Semisolid/ 
Watery 
Solid/ Semisolid/ 
Watery 
Stool bulk Normal/ Reduced Normal/ Reduced Normal/ Reduced 
Constipation Present/ Absent Present/ Absent Present/ Absent 
Diarrhoea Present/ Absent Present/ Absent Present/ Absent 
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8.MOOTHIRAM[URINE EXAMINATION]: 
NEERKURI 1
st
Day 05thDay 7th Day 
   am White/ White/ White/ 
[Colour] Yellowish/ Yellowish/ Yellowish/ 
 Straw Straw Straw 
 coloured/ Coloured/ coloured/ 
 Crystal Crystal Crystal 
 clear clear clear 
Maṇam [Odour] Present/ 
Absent 
Absent 
Present/ Absent 
 
Present/ Absent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II.THEGI: [TYPE OF BODY CONSTITUTION] 
III.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
Kurinji          Mullai        Marutham            Neithal              Palai 
IV.KAALAM: 
Kaarkalam  -   Pinpanikalam   - 
Koothirkalam  -   Ilavenil  - 
Munpanikalam -   Muthuvenil  - 
V.MUKKUTRAM:[AFFECTION OF THREE HUMORS]  
  
Nurai [Froth] Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Nil/Reduced/ 
Increased 
Eṭai [Sp.gravity] Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/R 
educed 
Normal/ 
Increased/R 
educed Eñcal [Deposits] Present/ 
Absent 
Present/ Absent Present/ Absent 
Volume Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/R 
educed 
Normal/ 
Increased/R 
educed 
NEIKURI 1
st
Day 05thDay 7th Day 
Serpentine fashion    
Annular/Ringed  fashion    
Pearl beaded fashion    
Mixed fashion    
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A)VATHAM: 
 1
st
Day 05thDay 7th Day 
P rāṇa     
 pā a     
V  ā a     
 tā a     
 amā ān    
 āka (Higher intellectual function)    
 ūrman (airway of yawning)    
  r kara  (Air of salivation/nasal  secrection)    
   atatta  (Air of laziness)    
 a a    a (this air that acts on death)    
B.PITHAM: 
 1
st
Day 05thDay 7th Day 
  a p ttam (Gastric juice)    
Irañcakappittam(Haemoglobin)    
 ātakapp ttam (Life energy)    
P rā akam (Bile)    
Ālō akam    
C.KABAM: 
 1
st
Day 05thDay 7th Day 
Avalampakam (Serum)    
  l takam (saliva)    
Pōtakam (lymph)    
 a pakam (cerebrospinal fluid)    
Cantikam(synovialfluid)    
VI.SEVEN DHATHUS: (7 SOMATIC COMPONENTS) 
 1
st
Day 05thDay 7th Day 
 āram [Chyme]    
Cennīr [Blood]    
Ūṇ [Muscle]    
 o  pp [Fat]    
  p  [Bones]    
 ūḷa  [Bonemarrow]    
Cukkilam [Genital  discharges]    
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1.SYSTEMIC EXAMINATION: 
 1
st
Day 05thDay 7th Day 
1)Gastrointestinal  System    
2) Respiratory System    
3)Cardiovascular  System    
4)Central Nervous System    
5)Urogenital System    
Anthropometry: 
 Height    : 
Weight    : 
Head Circumference   : 
Chest Circumference   : 
Mid Arm Circumference  : 
2. GENERAL EXAMINATION:18
th
 
3.CLINICAL SYMPTOMS: 
COMPLAINTS 
1-
3days 
6-8 
days 
 9-
10 
days 
11-
15 
days 
Above 
15 
days 
Unrecovered 
Loose stools with 
blood or mucus    
   
Abdominal pain       
Sore anus       
Flatulence       
Colour and smell of 
stools 
   
   
Vomiting       
Loss of appetite       
Urinary retention       
 
Date: 
 1
st
Day 03thDay 7th Day 
Height (cms)    
Weight (kg)    
Temperature (F0)    
Pulse rate (per min)    
Heart rate (per min)    
Respiratory rate(per min)    
Blood pressure (mm/Hg)    
Anaemia    
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Station 
Signature of the Investigator: 
Signature of the Guide                                                            Signature of the HOD 
 
GOVERNMENT SIDDHA MEDICAL 
COLLEGE&HOSPITALPALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF 
KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “            ”A PEDIATRIC  
DISORDER AND THE DRUG OF CHOICE IS            Ṉ      ṆAM 
S.I.No: ………….  OP/IP No: …………  Name: ……………… 
Age: …………….  Gender: …………..Date of Enrollment: …………. 
Date of Completion :…………. Informant:………….Reliability :  …………… 
FORM III – LABORATORY INVESTIGATION 
Routine blood investigations Normal values Before TMT 
date: 
After TMT 
date: 
Hb (gms%)    11.5- 14.5   
T.RBC (milli/cu.mm) 4-4.9   
ESR(mm) ½ hr. 0-4   
1hr. 0-13   
T.RBC (milli/cu.mm) 5000-14500   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
 
Urine Investigation Before TMT  
Date : 
After TMT  
Date : 
Albumin   
Sugar   
Deposits   
 
Stools Investigation Before TMT  
Date : 
After TMT  
Date : 
OVA   
Cyst   
Occult blood   
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Date : 
 
Signature of Guide:    Signature of Principal Investigator: 
 
Signature of HOD:  
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muRrpj;jkUj;Jtfy;Y}up kw;Wk; 
ghisaq;Nfhl;ilkUj;Jtkidgl;lNkw;gbg;GFoe;ijkUj;Jtj;Jiw 
Ngh;r;nrq;fha; fpUjk; gupfupg;Gj; jpwidf; fz;lwpAk; kUj;JtMa;T. 
xg;Gjy; gbtk; 
rhd;whsuhy; rhd;;wspf;fg;gl;lJ; 
 
 ehd; ,e;j kUj;Jt Ma;it Fwpj;j midj;J tpguq;fisAk; 
Nehahspapd; ngw;NwhUf;FGupAk; tifapy; vLj;Jiuj;Njd; 
vdcWjpmspf;fpNwd;. 
Njjp :        ifnahg;gk; : 
,lk; :        ngah; : 
Nehahspapd; ngw;Nwhh; xg;Gjy; gbtk; 
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;>kUe;jpd; jd;ikkw;Wk; 
kUj;Jt topKiwgw;wpAk;> ,e;j kUj;Jtj;ij njhlh;e;J vdJ Foe;ijapd; 
cly; ,af;fj;ijf; fz;fhzpf;fTk;>mjidg; ghJfhf;f gad;gLk; kUj;Jt 
Ma;Tf;$lg; gupNrhjidfs; gw;wpAk; jpUg;jp mspf;Fk; tifapy; 
Ma;TkUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
 ehd; ,e;j kUj;Jt Ma;tpd; NghJfhuzk; vJTk; $whky; vg;NghJ 
Ntz;LkhdhYk; vd; Foe;ijia tpLtpj;Jf; nfhs;Sk; cupikiaj; 
njupe;jpUf;fpNwd;. 
 ehd; vd;Dila Rje;jpukhf Njh;T nra;Ak; cupikiaf; nfhz;L Mkf; 
fopr;ry; Neha;f;fhd kUe;J gQ;r;rjPghf;fpdp #uzk; gupfupg;Gj; jpwid 
fz;lwpAk; kUj;Jt Ma;Tf;F vdJ Foe;ijia cl;gLj;j xg;Gjy; 
mspf;fpNwd;. 
,e;j Muha;r;rpf;Fjq;fs; tpUg;gj;jpd; Ngupy; Foe;ijia cl;gLj;Jk; 
gl;rj;jpy; cskUe;jhf Ngh;r;nrq;fha; fpUjk; 5ml, 18 ehl;fs; cl;nfhs;s 
Ntz;Lk;. 
 ,e;j Muha;r;rpapy; Nehapduhf Nrh;e;j gpwF cq;fSf;F tpUg;gk; 
,y;iynadpy; vg;nghOJ Ntz;LkhdhYk; jq;fsJ Foe;ijia tpyf;fpff; 
nfhs;syhk;. 
 NkYk; ,e;j Muha;r;rpf;FIEC (epWtdePjpnewpFO) rhd;Wngwg;gl;Ls;sJ. 
 ,e;jkUe;J rpwg;ghf Mkf; fopr;ry; Neha;f;fhf mq;fPfupf;fg;gl;l 
rpj;jkUj;Jt E}ypy; $wg;gl;Ls;sJ. ,J tiu Nehahspfsplk; ve;jtpj 
gf;ftpisTfis Vw;gLj;jtpy;iy. 
 NkYk; czTKiwapy; gj;jpak; fhf;FkhWmwpTWj;jg;gLfpwJ. 
 
Njjp :     ngw;Nwhh; ngah;  : 
,lk; :     ifnahg;gk;   
rhl;rpf;fhuh; ngah; : 
      ifnahg;gk;  : 
      cwTKiw  : 
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG. DEPT. OF KUZHANTHAI MARUTHUVAM 
       CONSENT FORM 
___________________________________________________ 
 
An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
Formulation “ a  at  ā   ṉ     aṇam” for the management “    
        ” 
CERTIFICATE BY INVESTIGATOR 
I certify that I have disclosed all the details about the study in the terms 
readily understood by the parent. 
Date ……………….      Signature………….. 
place ……………….     Name ……………… 
CONSENT OF INFORMANT 
I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up 
including the laboratory investigations to be performed to monitor and 
safeguardmy Son / Daughter body functions. 
I am aware of my right to opt out of the trial at any time during the 
courseofthe trial without having to give the reasons for doing so. 
I am, exercising my free power of choice; hereby give my consent to be 
included as a subject in the clinical trial of “ a  at  ā   ṉ     aṇam”for the 
treatment of “ ma  a    a ” 
Informant Signature:………. 
Date:        Informant Name: …………. 
Place:        Patient Name:………………. 
Signature of Witness     Relationship:…………………  
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GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAIPOST GRADUATE DEPARTMENT OF  
 
KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “            ”-A PEDIATRIC  
DISORDER AND THE DRUG OF CHOICE IS             Ṉ      ṆAM 
 
S.I.No: ………….        OP/IP No: …………  Name: ……………… 
Age: …………….  Gender:  …………..   Date of Enrollment: …………. 
Date of Completion :…………. Informant: …………. Reliability :  …………… 
 
FORM IVB – WITHDRAWAL 
 
Date of Trial commencement  : 
Date of withdrawal from trial  : 
Reason (s) for withdrawal   : Yes /No 
Long absence at reporting   : Yes /No 
Irregular treatment    : Yes /No 
Shift of locality    : Yes /No 
Complication adverse reactions if any: Yes /No 
Exacerbation of symptoms   : Yes /No 
Pt. not willing to continue  : Yes /No 
Date : 
 
 
Signature of Guide:    Signature of Principal Investigator:
  
 
 
Signature of HOD:  
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FORM IV-C – PATIENT INFORMATION SHEET 
Name of the principal investigator: 
……………………………………………………. 
Name of the institution  :  GOVERNMENT SIDDHA MEDICAL  
         COLLEGE&HOSPITAL, 
 Palayamkottai 
Information sheet for patients participating in the open clinical, trial  
1, _____________________________________ Studying as PG Scholar at  
GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL, 
PALAYAMKOTTAI  is doing a trail on the study “            ”.It  is a most 
common  disease in children. In this regard, I am in a need to ask you few questions. I 
will maintain confidentially of your comments and data obtained. There will be no 
risk of disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No 
compensation will be paid to you for taking part in this study.  
You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions.  
If you agree your child to be a participate in this study, he/she will be included 
in the study primarily by signing the concern form and then you will be given the 
internal medicine “            Ṉ      ṆAM” (250 – 300 mg)  for 7 days.  
 
Date : 
 
 
Signature of Guide:              Signature of Principal Investigator: 
 
 
Signature of HOD:  
 
 Annexure 39 
GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI 
MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “            ”-A 
PEDIATRIC DISORDER AND THE DRUG OF CHOICE IS 
            Ṉ      ṆAM 
FORM IVD- DIETARY ADVICE FORM 
 
S.I.No: ………….    OP/IP No: …………  Name: ……………… 
Age: ……………. Gender:  …………..   Date of Enrollment: …… 
Date of Completion :……… Informant: …………. Reliability :  …………… 
 
The following diet to be taken: The following food should be avoided 
 
• Drink adequatewater 
• Apple 
• Orange 
• Pomegranate 
• Nuts 
 
• Avoid bitter and sour taste 
foods  
• Milk and milk products 
• Agathi greens 
• Spicy foods 
• Chicken 
 
 
Date: 
Station: 
 
Signature of the Investigator: 
 
Signature of the Guide : 
    
        Signature of the HOD 
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Form – IVE 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR 
SIDDHA DRUGS 
Reporting Form For Suspected Adverse Reactions to Siddha Drugs 
 
Please Note: i. All Consumers/Patients and reporters information will remain 
confidential.  
  ii. It is requested to report all suspected reactions to the concerned,  
even if it does not have complete data, as soon as possible.  
Peripheral centre code :      State : 
. Patient /Consumer Identification (Please complete or tick boxes below as 
appropriate) 
Name  
 
 
Father Name  
 
Patient record no 
Ethnicity  
 
Occupation  
Address 
 
Village/Town 
Post/Via 
District /State 
Date of Birth/Age 
Sex:      Male /Female 
Weight: 
Degam: 
2. Description of the suspected adverse reactions please complete boxes below 
Date and time of initial 
observation  
 Season: 
Description of reaction   Geographical area: 
3. List of all medicines/Formulations including drugs of other systems used by 
the patient during the reporting period:  
Medicine 
Daily 
dose 
Route of 
administration  
Vehicle – 
Adjuvant 
Date 
Diagnosis for which 
medicine taken Starting Stopped 
Siddha 
 
     
Any other 
system of 
medicines  
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4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug  
a) Name of the Medicine   
b) Manufacturing unit and batch 
no. and date 
 
c) Expiry date  
d) Purchased and obtained from  
e) Composition of the formulation / 
part of the drug used 
 
2) Dietary restrictions if any 
3) Whether the drug is consumed under institutionally qualified medical 
supervision or used as self medication 
4) Any other relevant information  
5. Treatment provided for adverse reaction: 
6. The result of the adverse reaction /side effect / untoward effects ( Please 
complete the boxes below )  
Recovered Not 
recovered: 
 
Unknown Fatal If fatal 
Date of death: 
Severe Yes /No Reaction abated after drug stopped or dose reduced 
Reaction reappeared after re introduction : 
Was the patient admitted to hospital? 
If yes, give name and address of 
hospital 
 
 
7. Any laboratory investigation done to evaluate other possibilities? If yes 
specify: 
8. Whether the patient is suffering with any chronic disorders? 
 
9. H/O previous allergies /Drug reactions: 
 
10. Other illness (please describe): 
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Type (please tick):Nurse/Doctor/Pharmacist/Health 
worker/Patient/Attendant/Manufacturer/Distribution /Supplier /Any other    
(please Specify) 
Name : 
 
Address: 
 
Telephone /E-mail if any: 
 
 
Signature of the reporter      Date : 
 
Please send the completed from to  
 
From 
 
Government Siddha Medical College 
&Hospital, Palayamkottai, Post 
Graduate Department of Kuzhanthai 
Maruthuvam 
 
This Filled- in ADR report may be send within one month of observation / occurrence of ADR 
 
 
 
 
 
 
 
 
Date : 
Station: 
 
Signature of Investigator: 
 
Signature of Guide:     Signature of HOD  
To, 
The co-ordinator pharmacovigilence, 
Govt., Siddha Medical College and Hospital, 
Palayamkottai, 
Tirunelveli. 
Who can report?  
 Any health care professionals like Siddha Doctors /Nurses /Siddha 
Pharmacists /Patients Etc.,   
What to report? 
 All reactions, Drug interactions 
Confidentiality  
 The patient’s identify will be held in strict confidence and protected to 
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
BRANCH IV – KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI - 627 002. 
Form IVF -ADMISSION – DISCHARGE SHEET 
Name of the medical unit  :    Nationality  : 
I.P.No     :     Religion  : 
Bed No    :    Informant  : 
Name     :    Date of Admission : 
Age/Sex    :    Date of Discharge : 
Occupation(parents)   :    No. of days treated  : 
Income(parents)   :    Diagnosis  : 
S.No 
 
Clinical Features During 
admission 
During 
discharge 
1 Loose stools with mucus or blood   
2 Abdominal pain   
3 Flatulence   
4 Sore anus   
5 Loss of appetite   
6 Colour and smell of stools   
7 Vomiting   
8 Urinary retention   
 
 
 
Place: 
Date:            
           
      Signature of the Medical Officer 
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GOVERNMENT SIDDHA MEDICAL COLLEGE&HOSPITAL 
PALAYAMKOTTAI 
POST GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY ON “            ”-A PEDIATRIC 
DISORDER AND THE DRUG OF CHOICE IS             Ṉ      ṆAM 
FORM V-DRUG COMPLIANCE  
S.I.No: ………….  OP/IP No: ………… Name: ……………… 
Age: …………….  Gender: …………..  Date of Enrollment: …………. 
Date of Completion :…………. Informant:………..Reliability :  …………… 
 
NAME OF THE DRUG   :             Ṉ      ṆAM 
FORM OF THE DRUG    :     ṆAM 
ADMINISTRATION &ADJUVANT : PER ORAL  
DOSE & DURATION    : 250-300mg (based on duration and               
requirement) 
NO OF DRUG PACKS GIVEN   : ________________ 
NO OF DRUG PACKS  RETURNED : ________________ 
DAY 
DATE OF DRUG 
INTAKE 
MORNING EVENING 
DAY 1    
DAY 2    
DAY 3    
DAY 4    
DAY 5    
DAY 6    
DAY 7    
 
Date :                                                       Signature of Principal Investigator:  
 
  
 
Signature of the Guide: 
 
 
Signature of  HOD : 
